ClinicalTrials.gg
CompletedNCT01218438Updated Jul 20, 2021Results posted

Phase 2/3 Study of IGSC, 20% in PIDD

A Phase 2/3 interventional study of Immune Globulin Intravenous (Human), 10% Solution and Immune Globulin Subcutaneous (Human), 20% Solution in Primary Immunodeficiency Diseases (PID), sponsored by Baxalta now part of Shire. Completed at 18 sites in 2 countries. Open to participants aged 2 Years and older. Per ClinicalTrials.gov, last updated 2021-07-20.

Sponsored by Baxalta now part of Shire (part of Takeda) · Phase 2/3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
86
Allocation
Not applicable
Ages
2 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 27 studies testing Immunoglobulins, Intravenous in Primary Immunodeficiency Diseases — 2 open to participants now, 4 under way, 4 of them phase 3. Immunoglobulins, Intravenous · Primary Immunodeficiency Diseases.

Enrollment
2nd of 26
86 · median 45
Started
2013
with 1 other
Phase 2/3
3 of 27
none open now
Registered
9th of 27
by date
Lead sponsor
8 of 27
Baxalta now part of Shire

Among the 27 studies testing Immunoglobulins, Intravenous in Primary Immunodeficiency Diseases, this one is the 2nd largest by enrollment of the 26 interventional ones that give a count, is one of 2 that started in 2013, is one of 3 in phase 2/3, and was the 9th registered.

Primary Immunodeficiency Diseases

211 studies on the registry are indexed under Primary Immunodeficiency Diseases; 51 are open to participants now.

Browse Primary Immunodeficiency Diseases studies →

Open to participants now

2 of the 27 studies testing Immunoglobulins, Intravenous in Primary Immunodeficiency Diseases are open now. Recruiting first, the newest first:

All 2 open studies →

About Immunoglobulins, Intravenous

Immunoglobulins, Intravenous: first FDA approval 1944 (Baygam, Gamastan S/D), first EMA approval 2006. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 35 Primary Immunodeficiency Diseases studies recruiting now, 12 (34%) set no upper age limit and 10 (29%) stop at 75 or younger; 28 take children under 18; 11 take healthy volunteers.

This study: 2 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 27 studies testing Immunoglobulins, Intravenous in Primary Immunodeficiency Diseases, or all of them as a file.
02

Study summary

The purpose of this study is to develop a 20% subcutaneous (SC) immunoglobulin preparation for the treatment of patients with primary immunodeficiency diseases (PIDD).

03

Conditions studied

  • Primary Immunodeficiency Diseases (PID)
04

Who can participate

Ages eligible
2 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Main Inclusion Criteria:

  • Documented diagnosis of a form of primary humoral immunodeficiency involving defective antibody formation and requiring gammaglobulin replacement as defined according to the IUIS Scientific Committee, 2011 and by diagnostic criteria according to Conley et al. (1999). The diagnosis must be confirmed by the Medical Director prior to first treatment with the product (IP) in the study.
  • Participant is 2 years or older at the time of screening, and has a minimum body weight of 13 kg.
  • Written has been obtained from either the participant or the participant's legally authorized representative prior to any study-related procedures and study product administration
  • Participant has been receiving a stable monthly equivalent dose of IgG at an average minimum dose equivalent to 300 mg/kg bodyweight (BW)/4 weeks and a maximum dose equivalent to 1.0 gram/kg BW/4 weeks, for a minimum of 12 weeks prior to first treatment with the IP in the study.
  • Serum trough level of IgG > 500 mg/dL at screening
  • Participant is willing and able to comply with the requirements of the protocol

Main Exclusion Criteria:

  • Participant has known history of or is positive at screening for one or more of the following: surface antigen (HBsAg), polymerase chain reaction (PCR) for virus(HCV), PCR for (HIV) Type 1/2
  • Abnormal laboratory values at screening meeting any one of the following criteria (abnormal tests may be repeated once to determine if they are persistent):

    • Persistent (ALT) and aspartate amino transferase(AST) > 2.5 times the for the testing laboratory
    • Persistent severe neutropenia (defined as an [ANC] ≤500/mm\^3)
  • (CLcr) value that is \< 60% of normal for age and gender either measured, or calculated according to the Cockcroft-Gault formula
  • (other than adequately treated basal cell or squamous cell carcinoma of the skin or carcinoma in situ of the cervix), unless the disease-free period prior to screening exceeds 5 years
  • Participant is receiving anti-coagulation therapy (low dose aspirin at ≤325 mg/day is permitted) or has a history of thrombotic episodes (including deep vein thrombosis, myocardial infarction, cerebrovascular accident, pulmonary embolism) or sickle cell disease with crisis within 12 months prior to screening or a history of thrombophilia
  • Abnormal protein loss (protein losing enteropathy, nephrotic syndrome)
  • Anemia that would preclude phlebotomy for laboratory studies according to standard practice at the site
  • Acute serious bacterial infection within 3 months prior to screening
  • Ongoing history of or persistent reactions (urticaria, breathing difficulty, severe hypotension, or anaphylaxis) following intravenous immunoglobulin, subcutaneous immunoglobulin, and/or Immune Serum Globulin (ISG) infusions
  • Severe immunoglobulin A (IgA) deficiency (less than 0.07g/L) with known anti-IgA antibodies and a history of hypersensitivity
  • Participant is on continuous systemic antibacterial antibiotics at doses sufficient to treat or prevent bacterial infections, and, in the opinion of the investigator, cannot stop these for the duration of the study without putting the patient at risk of increased infections
  • Participant has active infection and is receiving antibiotic therapy for the treatment of infection at the time of screening
  • Bleeding disorder or thrombocytopenia with a count less than 20,000/μL, or who, in the opinion of the investigator, would be at significant risk of increased bleeding or bruising as a result of subcutaneous therapy
  • Total protein > 9 g/dL or myeloma or macroglobulinemia (IgM) or paraproteinemia
  • Severe dermatitis that would preclude adequate sites for safe product administration
  • Women of meeting any one of the following criteria:

    • Participant presents with a positive pregnancy test
    • Participant is breast feeding
    • Participant intends to begin nursing during the course of the study
    • Participant does not agree to employ adequate birth-control measures (e.g. intrauterine device, diaphragm or condom [for male partner] with spermicidal jelly or foam, or pills/patches) throughout the course of the study
  • Participation in another clinical study and exposure to an investigational product or device within 30 days prior to study enrollment (exception: treatment in a previous Baxter immunoglobulin study)
  • Participant is scheduled to participate in another (non-Baxter) non-observational (interventional) clinical study involving an investigational product or device during the course of the study
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
86 participants (actual)

Study arms

  • Experimental
    Study Epochs 1-4

    Epoch 1 (13 weeks): Pharmacokinetic (PK) assessment at 2nd to last infusion (in all participants ≥12 years of age). Participants will be treated intravenously once every 3 or 4 weeks at same monthly equivalent dose as prior to the study. Epoch 2 (12-16 weeks): PK assessment (in first 15 participants ≥12 years of age) at 9th infusion to determine adjusted dose for Epoch 3 and individually adapted dose for Epoch 4. Participants will be treated subcutaneously every 7 days at a dose of IGSC, 20% that is 145% of the weekly equivalent of the IV dose in Epoch 1. Epoch 3 (12 weeks): Participants will be treated subcutaneously every 7 days using the adjusted dose determined in Epoch 2. The individually adapted dose for use in Epoch 4 will also be determined. Epoch 4 (40 weeks): Participants will be treated subcutaneously once every week at the individually adapted dose determined in Epoch 3. PK assessment at 17th infusion.

    Biological: Immune Globulin Intravenous (Human), 10% Solution · Drug: Immune Globulin Subcutaneous (Human), 20% Solution

Interventions

06

What researchers measure

Primary outcomes

  1. Rate of Acute Serious Bacterial Infections Per Year (ASBI)

    Annual rate of validated acute serious bacterial infections was calculated using a Poisson model to account for the different lengths of observation per participant. The observation period for each participant starts with the day of the first subcutaneous (SC) infusion in Study Epoch 2 and ends with the day of the End of Study visit.

    Time frame: 1 year

Secondary outcomes

  1. Annual Rate of All Infections Per Participant

    Time frame: 1 year

  2. Annual Rate of Sinus Infections Per Participant

    Time frame: 1 year

  3. Annual Rate of Fever Episodes Per Participant

    Time frame: 1 year

  4. Annual Rate of Days Off School/Work or Days Unable to Perform Normal Daily Activities Due to Illness or Infection Per Participant

    Time frame: 1 year

  5. Annual Rate of Days on Antibiotics Per Participant

    Time frame: 1 year

  6. Annual Rate of Hospitalizations for Illness or Infection Per Participant

    Time frame: 1 year

  7. Annual Rate of Days of Hospitalizations for Illness or Infection Per Participant

    Time frame: 1 year

  8. Annual Rate of Acute (Urgent or Unscheduled) Physician Visits, or Visits to the Emergency Room for Illness or Infection Per Participant

    Time frame: 1 year

  9. Bioavailability of IGSC, 20% as Measured by the Ratio of the Geometric Means of Immunoglobulin G (IgG) AUCSC (Epoch 4) to IgG AUCIV,0-τ (Standardized to 1 Week) (Epoch 1) Adjusted for Dose and Dosing Frequency (Participants ≥12 Years Old)

    IGSC, 20% = Immune Globulin Subcutaneous (Human), 20% Solution; AUCSC = area under the concentration-time curve following subcutaneous administration; AUCIV,0-τ = area under the concentration-time curve following intravenous administration over a dosing interval

    Time frame: Epoch 1: 3 week IV administration interval: Week 10, 11, 12, 13. Epoch 1: 4 week IV interval: Week 9, 10, 11, 12, 13. Epoch 4 Subcutaneous administration weeks 17, 18

  10. Trough Levels of IgG (Total), and IgG Subclasses at the End of the Treatment Intervals

    Time frame: Epoch 1: 3 week IV interval- weeks 0, 1, 4, 7, 10, 13. Epoch 1: 4 week IV interval- weeks 0, 1, 5, 9, 13. Epochs 2 & 3: Subcutaneous (SC) weeks 5, 9. Epoch 4: SC weeks 1, 9, 17, 29, 40 (week dependent on time to establish "Adjusted Dose" in Epoch 2)

  11. Trough Levels of Anti-Tetanus Antibody

    Time frame: Epoch 1: 3 week IV interval- weeks 1, 4, 7, 10, 13. Epoch 1: 4 week IV interval- weeks 1, 5, 9, 13. Epochs 2 & 3: Subcutaneous (SC) weeks 5, 9. Epoch 4: SC weeks 1, 9, 17, 29, 40 (week dependent on time to establish "Adjusted Dose" in Epoch 2)

  12. Trough Levels of Anti-Haemophilus Influenza B Antibody

    Time frame: Epoch 1: 3 week IV interval- weeks 1, 4, 7, 10, 13. Epoch 1: 4 week IV interval- weeks 1, 5, 9, 13. Epochs 2 & 3: Subcutaneous (SC) weeks 5, 9. Epoch 4: SC weeks 1, 9, 17, 29, 40 (week dependent on time to establish "Adjusted Dose" in Epoch 2)

  13. Trough Levels of Anti-Hepatitis B Antibody

    Time frame: Epoch 1: 3 week IV interval- weeks 1, 4, 7, 10, 13. Epoch 1: 4 week IV interval- weeks 1, 5, 9, 13. Epochs 2 & 3: Subcutaneous (SC) weeks 5, 9. Epoch 4: SC weeks 1, 9, 17, 29, 40 (week dependent on time to establish "Adjusted Dose" in Epoch 2)

  14. Pharmacokinetics Parameters for Immunoglobulin G (IgG): Area Under the Curve (AUC)

    The AUC between adjacent infusions will be calculated by the trapezoidal rule. Linear interpolation/extrapolation will be used to calculate the AUC for exact duration of the infusion intervals (21 or 28 days for IV administration and 7 days for SC administration). To allow for comparisons between Epochs 1, 2 and 4, AUC0-τ will be standardized for the infusion intervals (3 or 4 weeks vs. 1 week)

    Time frame: Epoch 1: 3 week IV interval: Weeks 10-13. Epoch 1: 4 week IV interval: Weeks 9-13. Epoch 2: Subcutaneous (SC) weeks 9-10. Epoch 4: SC weeks 17-18

  15. Pharmacokinetics Parameters for Immunoglobulin G (IgG): Dose Per Weight-adjusted Area Under the Curve (AUC)

    The AUC between adjacent infusions will be calculated by the trapezoidal rule. Linear interpolation/extrapolation will be used to calculate the AUC for exact duration of the infusion intervals (21 or 28 days for IV administration and 7 days for SC administration). To allow for comparisons between Epochs 1, 2 and 4, AUC0-τ will be standardized for the infusion intervals (3 or 4 weeks vs. 1 week) adjusted for the dose per weight.

    Time frame: Epoch 1: 3 week IV interval: Weeks 10-13. Epoch 1: 4 week IV interval: Weeks 9-13. Epoch 2: Subcutaneous (SC) weeks 9-10. Epoch 4: SC weeks 17-18

  16. Pharmacokinetics Parameters for Immunoglobulin G (IgG): Clearance (CL) for Immune Globulin Administered Intravenously (IGIV) and Apparent Clearance for Immune Globulin Administered Subcutaneously (IGSC)

    Clearance (CL) or apparent clearance (CL/F) for IV and SC administration, respectively, will be determined by the formula: CL or CL/F = (Dose (mg/kg)) / (AUC 0-τ). (F= bioavailability)

    Time frame: Epoch 1: 3 week IV interval: Weeks 10-13. Epoch 1: 4 week IV interval: Weeks 9-13. Epoch 2: Subcutaneous (SC) weeks 9-10. Epoch 4: SC weeks 17-18

  17. Pharmacokinetics Parameters for Immunoglobulin G (IgG): Maximum Concentration (Cmax)

    The maximum concentration (Cmax) following administration of study drug (either immune globulin administered intravenously (IGIV) or immune globulin administered subcutaneously (IGSC).

    Time frame: Epoch 1: 3 week IV interval: Weeks 10-13. Epoch 1: 4 week IV interval: Weeks 9-13. Epoch 2: Subcutaneous (SC) weeks 9-10. Epoch 4: SC weeks 17-18

  18. Pharmacokinetics Parameters for Immunoglobulin G (IgG): Time to Maximum Concentration (Tmax)

    The minimum time (Tmax) to reach the maximum concentration (Cmax)

    Time frame: Epoch 1: 3 week IV interval: Weeks 10-13. Epoch 1: 4 week IV interval: Weeks 9-13. Epoch 2: Subcutaneous (SC) weeks 9-10. Epoch 4: SC weeks 17-18

  19. Pharmacokinetics Parameters for Immunoglobulin G (IgG): Minimum Concentration (Cmin)

    The minimum concentration (Cmax) following administration of study drug (either immune globulin administered intravenously (IGIV) or immune globulin administered subcutaneously (IGSC).

    Time frame: Epoch 1: 3 week IV interval: Weeks 10-13. Epoch 1: 4 week IV interval: Weeks 9-13. Epoch 2: Subcutaneous (SC) weeks 9-10. Epoch 4: SC weeks 17-18

  20. Pharmacokinetics Parameters for Haemophilus Influenza B Antibody: Area Under the Curve (AUC)

    The AUC between adjacent infusions will be calculated by the trapezoidal rule . Linear interpolation/extrapolation will be used to calculate the AUC for exact duration of the infusion intervals (21 or 28 days for IV administration and 7 days for SC administration). To allow for comparisons between Epochs 1, 2 and 4, AUC 0-τ will be standardized for the infusion intervals (3 or 4 weeks vs. 1 week )

    Time frame: Epoch 1: 3 week IV interval: Weeks 10-13. Epoch 1: 4 week IV interval: Weeks 9-13. Epoch 2: Subcutaneous (SC) weeks 9-10. Epoch 4: SC weeks 17-18

  21. Pharmacokinetics Parameters for Haemophilus Influenza B Antibody: Dose Per Weight-adjusted Area Under the Curve (AUC)

    The AUC between adjacent infusions will be calculated by the trapezoidal rule . Linear interpolation/extrapolation will be used to calculate the AUC for exact duration of the infusion intervals (21 or 28 days for IV administration and 7 days for SC administration). To allow for comparisons between Epochs 1, 2 and 4, AUC 0-τ will be standardized for the infusion intervals (3 or 4 weeks vs. 1 week) adjusted for the dose per weight.

    Time frame: Epoch 1: 3 week IV interval: Weeks 10-13. Epoch 1: 4 week IV interval: Weeks 9-13. Epoch 2: Subcutaneous (SC) weeks 9-10. Epoch 4: SC weeks 17-18

  22. Pharmacokinetics Parameters for Haemophilus Influenza B Antibody: Clearance (CL) for Immune Globulin Administered Intravenously (IGIV) and Apparent Clearance (CL/F) for Immune Globulin Administered Subcutaneously

    Clearance (CL) or apparent clearance (CL/F) for IV and SC administration, respectively, will be determined by the formula: CL or CL/F = (Dose (mg/kg)) / (AUC 0- τ). (F= bioavailability)

    Time frame: Epoch 1: 3 week IV interval: Weeks 10-13. Epoch 1: 4 week IV interval: Weeks 9-13. Epoch 2: Subcutaneous (SC) weeks 9-10. Epoch 4: SC weeks 17-18

  23. Pharmacokinetics Parameters for Haemophilus Influenza B Antibody: Maximum Concentration (Cmax)

    The maximum concentration (Cmax) following administration of study drug (either immune globulin administered intravenously (IGIV) or immune globulin administered subcutaneously (IGSC).

    Time frame: Epoch 1: 3 week IV interval: Weeks 10-13. Epoch 1: 4 week IV interval: Weeks 9-13. Epoch 2: Subcutaneous (SC) weeks 9-10. Epoch 4: SC weeks 17-18

  24. Pharmacokinetics Parameters for Haemophilus Influenza B Antibody: Time to Maximum Concentration (Tmax)

    The minimum time (Tmax) to reach the maximum concentration (Cmax)

    Time frame: Epoch 1: 3 week IV interval: Weeks 10-13. Epoch 1: 4 week IV interval: Weeks 9-13. Epoch 2: Subcutaneous (SC) weeks 9-10. Epoch 4: SC weeks 17-18

  25. Pharmacokinetics Parameters for Haemophilus Influenza B Antibody: Minimum Concentration (Cmin)

    The minimum concentration (Cmax) following administration of study drug (either immune globulin administered intravenously (IGIV) or immune globulin administered subcutaneously (IGSC).

    Time frame: Epoch 1: 3 week IV interval: Weeks 10-13. Epoch 1: 4 week IV interval: Weeks 9-13. Epoch 2: Subcutaneous (SC) weeks 9-10. Epoch 4: SC weeks 17-18

  26. Correction Factor to Determine the Individually Adapted Dose in Study 170904 Epoch 4 (Dose Adjustment Table)

    There is a high degree of variability in catabolism of immunoglobulin G (IgG) between individuals. To address this, trough levels immediately prior to the 9th weekly infusion in Epoch 3 were measured. The ratio of the measured trough levels on subcutaneous (SC) (Epoch 3) and intravenous (IV) administration (Epoch1) were compared to the expected trough level determined in Epoch 2. This was used to determine the Individually Adapted Dose to be used in Epoch 4. This was an interim study analysis.

    Time frame: 29 weeks

  27. Number of Serious (SAEs) and Non-serious Adverse Events (AEs) (Including and Excluding Infections) Deemed Related to the Investigational Product Per Participant

    Number of related SAEs and AEs divided by number of participants

    Time frame: Up to 20 months per subject (throughout entire study)

  28. Number of Serious (SAEs) and Non-serious Adverse Events (AEs) (Including and Excluding Infections) Deemed Related to the Investigational Product Per Infusion

    Number of related SAEs and AEs divided by number of subjects and divided by number of infusions

    Time frame: Up to 20 months per subject (throughout entire study)

  29. Number of Serious (SAEs) and Non-serious Adverse Events (AEs) (Including and Excluding Infections) Regardless of Relationship to the Investigational Product Per Participant

    Number of all SAEs and AEs divided by number of participants

    Time frame: Up to 20 months per subject (throughout entire study)

  30. Number of Serious (SAEs) and Non-serious Adverse Events (AEs) (Including and Excluding Infections) Regardless of Relationship to the Investigational Product Per Infusion

    Number of all SAEs and AEs divided by number of infusions

    Time frame: Up to 20 months per subject (throughout entire study)

  31. Number of Adverse Events (AEs) (Including and Excluding Infections) That Begin During or Within 72 Hours of Completion of Infusion Per Participant

    Number of AEs that begin during or within 72 hours of completion of infusion divided by number of participants

    Time frame: Within 72 hours of completion of infusion

  32. Number of Adverse Events (AEs) (Including and Excluding Infections) That Begin During or Within 72 Hours of Completion of Infusion Per Infusion

    Number of AEs that begin during or within 72 hours of completion of infusion divided by the number of infusions

    Time frame: Within 72 hours of completion of infusion

  33. Number of Adverse Events (AEs) (Including and Excluding Infections) That Begin During or Within 24 Hours of Completion of Infusion Per Participant

    Number of AEs that begin during or within 24 hours of completion of infusion divided by number of participants

    Time frame: Within 24 hours of completion of infusion

  34. Number of Adverse Events (AEs) (Including and Excluding Infections) That Begin During or Within 24 Hours of Completion of Infusion Per Infusion

    Number of AEs that begin during or within 24 hours of completion of infusion divided by number of infusions

    Time frame: Within 24 hours of completion of infusion

  35. Number of Adverse Events (AEs) (Including and Excluding Infections) That Begin During or Within 1 Hour of Completion of Infusion Per Participant

    Number of AEs that begin during or within 1 hour of completion of infusion divided by number of participants

    Time frame: Within 1 hour of completion of infusion

  36. Number of Adverse Events (AEs) (Including and Excluding Infections) That Begin During or Within 1 Hour of Completion of Infusion

    Number of AEs that begin during or within 1 hour of completion of infusion divided by number of infusions

    Time frame: Within 1 hour of completion of infusion

  37. Causally Related and/or Temporally Associated Adverse Events (AEs) Per Infusion

    The total number of all AEs (including and excluding infections) that begin during infusion or within 72 hours of completion of an infusion ("temporally associated") plus the total number of AEs (including and excluding infections) starting more than 72 hours following the completion of an infusion determined by the investigator to be at least possibly related to the study drug("related"), divided by the total number of infusions

    Time frame: Within 72 hours post infusion for Temporally Associated AEs; End of each Study Epoch (Epoch 1, Epoch 2, Epoch 3, and Epoch 4) for Causally Related AEs

  38. Percentage of Infusions Associated With One or More Local Non-serious Adverse Events (Non-SAEs)

    The number of infusions associated with local non-SAEs divided by the total number of infusions.

    Time frame: Up to 20 months (throughout entire study)

  39. Percentage of Participants Reporting One or More Local Non-serious Adverse Events (Non-SAEs)

    Time frame: Up to 20 months (throughout entire study)

  40. Number of Infusions for Which the Infusion Rate Was Reduced and/or the Infusion Was Interrupted or Stopped Due to Tolerability Concerns or AEs

    Time frame: Up to 20 months (throughout entire study)

  41. Percentage of Participants for Whom the Infusion Rate Was Reduced and/or the Infusion Was Interrupted or Stopped Due to Tolerability Concerns or AEs

    Time frame: Up to 20 months (throughout entire study)

  42. Percentage of Infusions Tolerated With Intravenous or Subcutaneous Administration

    An infusion will be deemed as tolerated unless one of the following occurs: 1. Any serious related AE(s) 2. Any non-serious local or systemic related AE(s) that prevent(s) completion of infusion 3. Any severe non-serious local or systemic related AE(s) that occur within 60 minutes of completion of the infusion

    Time frame: Up to 20 months (throughout entire study)

  43. Short Term Tolerance - Change in Systolic Blood Pressure: Immune Globulin Administered Intravenously (Human), 10% (IV 10%), Infusion 1

    Vital signs measured pre-infusion, during infusion, and post-infusion of Immune globulin administered intravenously (Human), 10% (IV 10%) was graded by the investigator and the sponsor using a 4-grade scale: mild (grade 1), moderate (grade 2), severe (grade 3) or life-threatening (grade 4) according to the U.S. Department of Health and Human Services, Food and Drug Administration, Center for Biologics Evaluation and Research; Guidance for Industry - Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials, September2007. \*Note 5th Grade (grade 0) added to scale to reflect within normal range.

    Time frame: Within 30 minutes pre-infusion, during infusion and within 30 minutes post infusion

  44. Short Term Tolerance - Change in Systolic Blood Pressure: Immune Globulin Administered Intravenously (Human), 10% (IV 10%), Infusion 2

    Vital signs measured pre-infusion, during infusion, and post-infusion of Immune globulin administered intravenously (Human), 10% (IV 10%) was graded by the investigator and the sponsor using a 4-grade scale: mild (grade 1), moderate (grade 2), severe (grade 3) or life-threatening (grade 4) according to the U.S. Department of Health and Human Services, Food and Drug Administration, Center for Biologics Evaluation and Research; Guidance for Industry - Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials, September2007. \*Note 5th Grade (grade 0) added to scale to reflect within normal range.

    Time frame: Within 30 minutes pre-infusion, during infusion and within 30 minutes post infusion

  45. Short Term Tolerance - Change in Systolic Blood Pressure: Immune Globulin Administered Intravenously (Human), 10% (IV 10%), Infusion 3

    Vital signs measured pre-infusion, during infusion, and post-infusion of Immune globulin administered intravenously (Human), 10% (IV 10%) was graded by the investigator and the sponsor using a 4-grade scale: mild (grade 1), moderate (grade 2), severe (grade 3) or life-threatening (grade 4) according to the U.S. Department of Health and Human Services, Food and Drug Administration, Center for Biologics Evaluation and Research; Guidance for Industry - Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials, September2007. \*Note 5th Grade (grade 0) added to scale to reflect within normal range.

    Time frame: Within 30 minutes pre-infusion, during infusion and within 30 minutes post infusion

  46. Short Term Tolerance - Change in Systolic Blood Pressure: Immune Globulin Administered Subcutaneously (Human), 20% (SC 20%), Infusion 1

    Vital signs measured pre-infusion, during infusion, and post-infusion of Immune globulin administered subcutaneously (Human), 20% (SC 20%) was graded by the investigator and the sponsor using a 4-grade scale: mild (grade 1), moderate (grade 2), severe (grade 3) or life-threatening (grade 4) according to the U.S. Department of Health and Human Services, Food and Drug Administration, Center for Biologics Evaluation and Research; Guidance for Industry - Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials, September2007. \*Note 5th Grade (grade 0) added to scale to reflect within normal range.

    Time frame: Within 30 minutes pre-infusion, during infusion and within 30 minutes post infusion

  47. Short Term Tolerance - Change in Systolic Blood Pressure: Immune Globulin Administered Subcutaneously (Human), 20% (SC 20%), Infusion 2

    Vital signs measured pre-infusion, during infusion, and post-infusion of Immune globulin administered subcutaneously (Human), 20% (SC 20%) was graded by the investigator and the sponsor using a 4-grade scale: mild (grade 1), moderate (grade 2), severe (grade 3) or life-threatening (grade 4) according to the U.S. Department of Health and Human Services, Food and Drug Administration, Center for Biologics Evaluation and Research; Guidance for Industry - Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials, September2007. \*Note 5th Grade (grade 0) added to scale to reflect within normal range.

    Time frame: Within 30 minutes pre-infusion, during infusion and within 30 minutes post infusion

  48. Short Term Tolerance - Change in Systolic Blood Pressure: Immune Globulin Administered Subcutaneously (Human), 20% (SC 20%), Infusion 3

    Vital signs measured pre-infusion, during infusion, and post-infusion of Immune globulin administered subcutaneously (Human), 20% (SC 20%) was graded by the investigator and the sponsor using a 4-grade scale: mild (grade 1), moderate (grade 2), severe (grade 3) or life-threatening (grade 4) according to the U.S. Department of Health and Human Services, Food and Drug Administration, Center for Biologics Evaluation and Research; Guidance for Industry - Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials, September2007. \*Note 5th Grade (grade 0) added to scale to reflect within normal range.

    Time frame: Within 30 minutes pre-infusion, during infusion and within 30 minutes post infusion

  49. Short Term Tolerance - Change in Diastolic Blood Pressure: Immune Globulin Administered Intravenously (Human), 10% (IV 10%), Infusion 1

    Vital signs measured pre-infusion, during infusion, and post-infusion of Immune globulin administered intravenously (Human), 10% (IV 10%) was graded by the investigator and the sponsor using a 4-grade scale: mild (grade 1), moderate (grade 2), severe (grade 3) or life-threatening (grade 4) according to the U.S. Department of Health and Human Services, Food and Drug Administration, Center for Biologics Evaluation and Research; Guidance for Industry - Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials, September2007. \*Note 5th Grade (grade 0) added to scale to reflect within normal range.

    Time frame: Within 30 minutes pre-infusion, during infusion and within 30 minutes post infusion

  50. Short Term Tolerance - Change in Diastolic Blood Pressure: Immune Globulin Administered Intravenously (Human), 10% (IV 10%), Infusion 2

    Vital signs measured pre-infusion, during infusion, and post-infusion of Immune globulin administered intravenously (Human), 10% (IV 10%) was graded by the investigator and the sponsor using a 4-grade scale: mild (grade 1), moderate (grade 2), severe (grade 3) or life-threatening (grade 4) according to the U.S. Department of Health and Human Services, Food and Drug Administration, Center for Biologics Evaluation and Research; Guidance for Industry - Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials, September2007. \*Note 5th Grade (grade 0) added to scale to reflect within normal range.

    Time frame: Within 30 minutes pre-infusion, during infusion and within 30 minutes post infusion

  51. Short Term Tolerance - Change in Diastolic Blood Pressure: Immune Globulin Administered Intravenously (Human), 10% (IV 10%), Infusion 3

    Vital signs measured pre-infusion, during infusion, and post-infusion of Immune globulin administered intravenously (Human), 10% (IV 10%) was graded by the investigator and the sponsor using a 4-grade scale: mild (grade 1), moderate (grade 2), severe (grade 3) or life-threatening (grade 4) according to the U.S. Department of Health and Human Services, Food and Drug Administration, Center for Biologics Evaluation and Research; Guidance for Industry - Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials, September2007. \*Note 5th Grade (grade 0) added to scale to reflect within normal range.

    Time frame: Within 30 minutes pre-infusion, during infusion and within 30 minutes post infusion

  52. Short Term Tolerance - Change in Diastolic Blood Pressure: Immune Globulin Administered Subcutaneously (Human), 20% (SC 20%), Infusion 1

    Vital signs measured pre-infusion, during infusion, and post-infusion of Immune globulin administered subcutaneously (Human), 20% (SC 20%) was graded by the investigator and the sponsor using a 4-grade scale: mild (grade 1), moderate (grade 2), severe (grade 3) or life-threatening (grade 4) according to the U.S. Department of Health and Human Services, Food and Drug Administration, Center for Biologics Evaluation and Research; Guidance for Industry - Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials, September2007. \*Note 5th Grade (grade 0) added to scale to reflect within normal range.

    Time frame: Within 30 minutes pre-infusion, during infusion and within 30 minutes post infusion

  53. Short Term Tolerance - Change in Diastolic Blood Pressure: Immune Globulin Administered Subcutaneously (Human), 20% (SC 20%), Infusion 2

    Vital signs measured pre-infusion, during infusion, and post-infusion of Immune globulin administered subcutaneously (Human), 20% (SC 20%) was graded by the investigator and the sponsor using a 4-grade scale: mild (grade 1), moderate (grade 2), severe (grade 3) or life-threatening (grade 4) according to the U.S. Department of Health and Human Services, Food and Drug Administration, Center for Biologics Evaluation and Research; Guidance for Industry - Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials, September2007. \*Note 5th Grade (grade 0) added to scale to reflect within normal range.

    Time frame: Within 30 minutes pre-infusion, during infusion and within 30 minutes post infusion

  54. Short Term Tolerance - Change in Diastolic Blood Pressure: Immune Globulin Administered Subcutaneously (Human), 20% (SC 20%), Infusion 3

    Vital signs measured pre-infusion, during infusion, and post-infusion of Immune globulin administered subcutaneously (Human), 20% (SC 20%) was graded by the investigator and the sponsor using a 4-grade scale: mild (grade 1), moderate (grade 2), severe (grade 3) or life-threatening (grade 4) according to the U.S. Department of Health and Human Services, Food and Drug Administration, Center for Biologics Evaluation and Research; Guidance for Industry - Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials, September2007. \*Note 5th Grade (grade 0) added to scale to reflect within normal range.

    Time frame: Within 30 minutes pre-infusion, during infusion and within 30 minutes post infusion

  55. Short Term Tolerance - Change in Heart Rate (Pulse): Immune Globulin Administered Intravenously (Human), 10% (IV 10%), Infusion 1

    Vital signs measured pre-infusion, during infusion, and post-infusion of Immune globulin administered intravenously (Human), 10% (IV 10%) was graded by the investigator and the sponsor using a 4-grade scale: mild (grade 1), moderate (grade 2), severe (grade 3) or life-threatening (grade 4) according to the U.S. Department of Health and Human Services, Food and Drug Administration, Center for Biologics Evaluation and Research; Guidance for Industry - Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials, September2007. \*Note 5th Grade (grade 0) added to scale to reflect within normal range.

    Time frame: Within 30 minutes pre-infusion, during infusion and within 30 minutes post infusion

  56. Short Term Tolerance - Change in Heart Rate (Pulse): Immune Globulin Administered Intravenously (Human), 10% (IV 10%), Infusion 2

    Vital signs measured pre-infusion, during infusion, and post-infusion of Immune globulin administered intravenously (Human), 10% (IV 10%) was graded by the investigator and the sponsor using a 4-grade scale: mild (grade 1), moderate (grade 2), severe (grade 3) or life-threatening (grade 4) according to the U.S. Department of Health and Human Services, Food and Drug Administration, Center for Biologics Evaluation and Research; Guidance for Industry - Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials, September2007. \*Note 5th Grade (grade 0) added to scale to reflect within normal range.

    Time frame: Within 30 minutes pre-infusion, during infusion and within 30 minutes post infusion

  57. Short Term Tolerance - Change in Heart Rate (Pulse): Immune Globulin Administered Intravenously (Human), 10% (IV 10%), Infusion 3

    Vital signs measured pre-infusion, during infusion, and post-infusion of Immune globulin administered intravenously (Human), 10% (IV 10%) was graded by the investigator and the sponsor using a 4-grade scale: mild (grade 1), moderate (grade 2), severe (grade 3) or life-threatening (grade 4) according to the U.S. Department of Health and Human Services, Food and Drug Administration, Center for Biologics Evaluation and Research; Guidance for Industry - Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials, September2007. \*Note 5th Grade (grade 0) added to scale to reflect within normal range.

    Time frame: Within 30 minutes pre-infusion, during infusion and within 30 minutes post infusion

  58. Short Term Tolerance - Change in Heart Rate (Pulse): Immune Globulin Administered Subcutaneously (Human), 20% (SC 20%), Infusion 1

    Vital signs measured pre-infusion, during infusion, and post-infusion of Immune globulin administered subcutaneously (Human), 20% (SC 20%) was graded by the investigator and the sponsor using a 4-grade scale: mild (grade 1), moderate (grade 2), severe (grade 3) or life-threatening (grade 4) according to the U.S. Department of Health and Human Services, Food and Drug Administration, Center for Biologics Evaluation and Research; Guidance for Industry - Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials, September2007. \*Note 5th Grade (grade 0) added to scale to reflect within normal range.

    Time frame: Within 30 minutes pre-infusion, during infusion and within 30 minutes post infusion

  59. Short Term Tolerance - Change in Heart Rate (Pulse): Immune Globulin Administered Subcutaneously (Human), 20% (SC 20%), Infusion 2

    Vital signs measured pre-infusion, during infusion, and post-infusion of Immune globulin administered subcutaneously (Human), 20% (SC 20%) was graded by the investigator and the sponsor using a 4-grade scale: mild (grade 1), moderate (grade 2), severe (grade 3) or life-threatening (grade 4) according to the U.S. Department of Health and Human Services, Food and Drug Administration, Center for Biologics Evaluation and Research; Guidance for Industry - Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials, September2007. \*Note 5th Grade (grade 0) added to scale to reflect within normal range.

    Time frame: Within 30 minutes pre-infusion, during infusion and within 30 minutes post infusion

  60. Short Term Tolerance - Change in Heart Rate (Pulse): Immune Globulin Administered Subcutaneously (Human), 20% (SC 20%), Infusion 3

    Vital signs measured pre-infusion, during infusion, and post-infusion of Immune globulin administered subcutaneously (Human), 20% (SC 20%) was graded by the investigator and the sponsor using a 4-grade scale: mild (grade 1), moderate (grade 2), severe (grade 3) or life-threatening (grade 4) according to the U.S. Department of Health and Human Services, Food and Drug Administration, Center for Biologics Evaluation and Research; Guidance for Industry - Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials, September2007. \*Note 5th Grade (grade 0) added to scale to reflect within normal range.

    Time frame: Within 30 minutes pre-infusion, during infusion and within 30 minutes post infusion

  61. Short Term Tolerance - Change in Respiratory Rate: Immune Globulin Administered Intravenously (Human), 10% (IV 10%), Infusion 1

    Vital signs measured pre-infusion, during infusion, and post-infusion of Immune globulin administered intravenously (Human), 10% (IV 10%) was graded by the investigator and the sponsor using a 4-grade scale: mild (grade 1), moderate (grade 2), severe (grade 3) or life-threatening (grade 4) according to the U.S. Department of Health and Human Services, Food and Drug Administration, Center for Biologics Evaluation and Research; Guidance for Industry - Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials, September2007. \*Note 5th Grade (grade 0) added to scale to reflect within normal range.

    Time frame: Within 30 minutes pre-infusion, during infusion and within 30 minutes post infusion

  62. Short Term Tolerance - Change in Respiratory Rate: Immune Globulin Administered Intravenously (Human), 10% (IV 10%), Infusion 2

    Vital signs measured pre-infusion, during infusion, and post-infusion of Immune globulin administered intravenously (Human), 10% (IV 10%) was graded by the investigator and the sponsor using a 4-grade scale: mild (grade 1), moderate (grade 2), severe (grade 3) or life-threatening (grade 4) according to the U.S. Department of Health and Human Services, Food and Drug Administration, Center for Biologics Evaluation and Research; Guidance for Industry - Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials, September2007. \*Note 5th Grade (grade 0) added to scale to reflect within normal range.

    Time frame: Within 30 minutes pre-infusion, during infusion and within 30 minutes post infusion

  63. Short Term Tolerance - Change in Respiratory Rate: Immune Globulin Administered Intravenously (Human), 10% (IV 10%), Infusion 3

    Vital signs measured pre-infusion, during infusion, and post-infusion of Immune globulin administered intravenously (Human), 10% (IV 10%) was graded by the investigator and the sponsor using a 4-grade scale: mild (grade 1), moderate (grade 2), severe (grade 3) or life-threatening (grade 4) according to the U.S. Department of Health and Human Services, Food and Drug Administration, Center for Biologics Evaluation and Research; Guidance for Industry - Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials, September2007. \*Note 5th Grade (grade 0) added to scale to reflect within normal range.

    Time frame: Within 30 minutes pre-infusion, during infusion and within 30 minutes post infusion

  64. Short Term Tolerance - Change in Respiratory Rate: Immune Globulin Administered Subcutaneously (Human), 20% (SC 20%), Infusion 1

    Vital signs measured pre-infusion, during infusion, and post-infusion of Immune globulin administered subcutaneously (Human), 20% (SC 20%) was graded by the investigator and the sponsor using a 4-grade scale: mild (grade 1), moderate (grade 2), severe (grade 3) or life-threatening (grade 4) according to the U.S. Department of Health and Human Services, Food and Drug Administration, Center for Biologics Evaluation and Research; Guidance for Industry - Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials, September2007. \*Note 5th Grade (grade 0) added to scale to reflect within normal range.

    Time frame: Within 30 minutes pre-infusion, during infusion and within 30 minutes post infusion

  65. Short Term Tolerance - Change in Respiratory Rate: Immune Globulin Administered Subcutaneously (Human), 20% (SC 20%), Infusion 2

    Vital signs measured pre-infusion, during infusion, and post-infusion of Immune globulin administered subcutaneously (Human), 20% (SC 20%) was graded by the investigator and the sponsor using a 4-grade scale: mild (grade 1), moderate (grade 2), severe (grade 3) or life-threatening (grade 4) according to the U.S. Department of Health and Human Services, Food and Drug Administration, Center for Biologics Evaluation and Research; Guidance for Industry - Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials, September2007. \*Note 5th Grade (grade 0) added to scale to reflect within normal range.

    Time frame: Within 30 minutes pre-infusion, during infusion and within 30 minutes post infusion

  66. Short Term Tolerance - Change in Respiratory Rate: Immune Globulin Administered Subcutaneously (Human), 20% (SC 20%), Infusion 3

    Vital signs measured pre-infusion, during infusion, and post-infusion of Immune globulin administered subcutaneously (Human), 20% (SC 20%) was graded by the investigator and the sponsor using a 4-grade scale: mild (grade 1), moderate (grade 2), severe (grade 3) or life-threatening (grade 4) according to the U.S. Department of Health and Human Services, Food and Drug Administration, Center for Biologics Evaluation and Research; Guidance for Industry - Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials, September2007. \*Note 5th Grade (grade 0) added to scale to reflect within normal range.

    Time frame: Within 30 minutes pre-infusion, during infusion and within 30 minutes post infusion

  67. Short Term Tolerance - Change in Body Temperature: Immune Globulin Administered Intravenously (Human), 10% (IV 10%), Infusion 1

    Vital signs measured pre-infusion, during infusion, and post-infusion of Immune globulin administered subcutaneously (Human), 20% (SC 20%) was graded by the investigator and the sponsor using a 4-grade scale: mild (grade 1), moderate (grade 2), severe (grade 3) or life-threatening (grade 4) according to the U.S. Department of Health and Human Services, Food and Drug Administration, Center for Biologics Evaluation and Research; Guidance for Industry - Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials, September2007. \*Note 5th Grade (grade 0) added to scale to reflect within normal range.

    Time frame: Within 30 minutes pre-infusion, during infusion and within 30 minutes post infusion

  68. Short Term Tolerance - Change in Body Temperature: Immune Globulin Administered Intravenously (Human), 10% (IV 10%), Infusion 2

    Vital signs measured pre-infusion, during infusion, and post-infusion of Immune globulin administered intravenously (Human), 10% (IV 10%) was graded by the investigator and the sponsor using a 4-grade scale: mild (grade 1), moderate (grade 2), severe (grade 3) or life-threatening (grade 4) according to the U.S. Department of Health and Human Services, Food and Drug Administration, Center for Biologics Evaluation and Research; Guidance for Industry - Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials, September2007. \*Note 5th Grade (grade 0) added to scale to reflect within normal range.

    Time frame: Within 30 minutes pre-infusion, during infusion and within 30 minutes post infusion

  69. Short Term Tolerance - Change in Body Temperature: Immune Globulin Administered Intravenously (Human), 10% (IV 10%), Infusion 3

    Vital signs measured pre-infusion, during infusion, and post-infusion of Immune globulin administered intravenously (Human), 10% (IV 10%) was graded by the investigator and the sponsor using a 4-grade scale: mild (grade 1), moderate (grade 2), severe (grade 3) or life-threatening (grade 4) according to the U.S. Department of Health and Human Services, Food and Drug Administration, Center for Biologics Evaluation and Research; Guidance for Industry - Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials, September2007. \*Note 5th Grade (grade 0) added to scale to reflect within normal range.

    Time frame: Within 30 minutes pre-infusion, during infusion and within 30 minutes post infusion

  70. Short Term Tolerance - Change in Body Temperature: Immune Globulin Administered Subcutaneously (Human), 20% (SC 20%), Infusion 1

    Vital signs measured pre-infusion, during infusion, and post-infusion of Immune globulin administered subcutaneously (Human), 20% (SC 20%) was graded by the investigator and the sponsor using a 4-grade scale: mild (grade 1), moderate (grade 2), severe (grade 3) or life-threatening (grade 4) according to the U.S. Department of Health and Human Services, Food and Drug Administration, Center for Biologics Evaluation and Research; Guidance for Industry - Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials, September2007. \*Note 5th Grade (grade 0) added to scale to reflect within normal range.

    Time frame: Within 30 minutes pre-infusion, during infusion and within 30 minutes post infusion

  71. Short Term Tolerance - Change in Body Temperature: Immune Globulin Administered Subcutaneously (Human), 20% (SC 20%), Infusion 2

    Vital signs measured pre-infusion, during infusion, and post-infusion of Immune globulin administered subcutaneously (Human), 20% (SC 20%) was graded by the investigator and the sponsor using a 4-grade scale: mild (grade 1), moderate (grade 2), severe (grade 3) or life-threatening (grade 4) according to the U.S. Department of Health and Human Services, Food and Drug Administration, Center for Biologics Evaluation and Research; Guidance for Industry - Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials, September2007. \*Note 5th Grade (grade 0) added to scale to reflect within normal range.

    Time frame: Within 30 minutes pre-infusion, during infusion and within 30 minutes post infusion

  72. Short Term Tolerance - Change in Body Temperature: Immune Globulin Administered Subcutaneously (Human), 20% (SC 20%), Infusion 3

    Vital signs measured pre-infusion, during infusion, and post-infusion of Immune globulin administered subcutaneously (Human), 20% (SC 20%) was graded by the investigator and the sponsor using a 4-grade scale: mild (grade 1), moderate (grade 2), severe (grade 3) or life-threatening (grade 4) according to the U.S. Department of Health and Human Services, Food and Drug Administration, Center for Biologics Evaluation and Research; Guidance for Industry - Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials, September2007. \*Note 5th Grade (grade 0) added to scale to reflect within normal range.

    Time frame: Within 30 minutes pre-infusion, during infusion and within 30 minutes post infusion

  73. Number of Participants With Laboratory Confirmed Hemolysis That Occurred Following Investigational Product Administration

    Laboratory tests for confirmation of potential hemolysis include Coomb's test, haptoglobin, free hemoglobin, reticulocyte count, lactate dehydrogenase (LDH), and urine hemosiderin.

    Time frame: Epoch 1: 3 week IV interval- weeks 0, 10. Epoch 1: 4 week IV interval- weeks 0, 9. Epoch 3: Subcutaneous (SC) week 9. Epoch 4: SC weeks 17, 18, 40

  74. Quality of Life- Pediatric Quality of Life Inventory^TM (PEDS-QL^TM) (Observer: Parent) for the Age Group 2 to 7 Years

    The Peds-QL is a generic Health-Related Quality of Life (HR QoL) instrument designed specifically for a pediatric population. It captures the following domains: general health/activities, feelings/emotional, social functioning, school functioning. Higher scores indicate better quality of life (QoL) for all domains of the Peds-QL. This modular instrument uses a 5-point scale: from 0 (never) to 4 (almost always). Items are reversed scored and linearly transformed to a 0-100 scale as follows: 0=100, 1=75, 2=50, 3=25, 4=0. 4 dimensions (physical, emotional, social, \& school functioning) are scored. 2 summary scores (Psychosocial Health Summary, and Physical Health Summary) are presented, along with a total score.

    Time frame: Up to 20 months (throughout entire study)

  75. Quality of Life- PEDS-QL^TM (Observer: Participant) for the Age Group 8 to 13 Years of Age

    The Peds-QL is a generic Health-Related Quality of Life (HR QoL) instrument designed specifically for a pediatric population. It captures the following domains: general health/activities, feelings/emotional, social functioning, school functioning. Higher scores indicate better quality of life (QoL) for all domains of the Peds-QL. This modular instrument uses a 5-point scale: from 0 (never) to 4 (almost always). Items are reversed scored and linearly transformed to a 0-100 scale as follows: 0=100, 1=75, 2=50, 3=25, 4=0. 4 dimensions (physical, emotional, social, \& school functioning) are scored. 2 summary scores (Psychosocial Health Summary, and Physical Health Summary) are presented, along with a total score.

    Time frame: Up to 20 months (throughout entire study)

  76. Quality of Life- Short-Form 36v2 (SF-36v2) for the Age Group 14 Years and Older

    The PCS is a summary scale of the dimensions physical functioning, role physical, bodily pain, and general health. The component score is normalized to a standard population. Scores range from 0 to 100 with higher scores representing better health. There is no total overall score; scoring is done for both sub-scores and summary scores.

    Time frame: Up to 20 months (throughout entire study)

  77. Treatment Satisfaction Questionnaire for Medication (TSQM) - 2 to 12 Years Old

    TSQM; for the age group 2 to 12 years the observer will be a parent. Treatment Satisfaction Questionnaire for Medication (TSQM) is a global satisfaction scale used to assess the overall level of participant's satisfaction or dissatisfaction with their medications. The following 3 domain were included: effectiveness, convenience, and global satisfaction. The score of each of the 3 domains is based on an algorithm to create a score of 0 to 100. Higher score indicated greater satisfaction in that domain.

    Time frame: Up to 20 months per subject (throughout entire study)

  78. Treatment Satisfaction Questionnaire for Medication (TSQM) - 13 Years and Older

    TSQM; for the age group 13 years and older the observer will be the participant. Treatment Satisfaction Questionnaire for Medication (TSQM) is a global satisfaction scale used to assess the overall level of participant's satisfaction or dissatisfaction with their medications. The following 3 domain were included: effectiveness, convenience, and global satisfaction. The score of each of the 3 domains is based on an algorithm to create a score of 0 to 100. Higher score indicated greater satisfaction in that domain.

    Time frame: Up to 20 months per subject (throughout entire study)

  79. Life Quality Index - 2 to 12 Years Old

    For the age group 2 to 12 years the respondent will be a parent. Each of the four domains has a separate score, each has a different range as follows: Treatment Interference Score Range: 6-42, Therapy-related Problems Score Range: 4-28, Therapy Setting Score Range: 3-21, Cost Score Range: 2-14. Higher scores represent more satisfaction with various aspects of treatment.

    Time frame: Up to 20 months (throughout entire study)

  80. Life Quality Index - 13 Years and Older

    For the age group 13 years and older the respondent will be the participant. Each of the four domains has a separate score, each has a different range as follows: Treatment Interference Score Range: 6-42, Therapy-related Problems Score Range: 4-28, Therapy Setting Score Range: 3-21, Cost Score Range: 2-14. Higher scores represent more satisfaction with various aspects of treatment.

    Time frame: Up to 20 months per subject (throughout entire study)

07

Results

Posted Feb 15, 2017

Participant flow

Participants were enrolled (signed informed consent) at 15 sites.

Epoch 1
Participant flow — Epoch 1
MilestoneStudy Participants
Started77
Completed74
Not completed3
Withdrew: Physician decision2
Withdrew: Adverse event1
Epoch 2
Participant flow — Epoch 2
MilestoneStudy Participants
Started45
Completed45
Not completed0
Epoch 3
Participant flow — Epoch 3
MilestoneStudy Participants
Started74
Completed70
Not completed4
Withdrew: Withdrawal by subject3
Withdrew: Adverse event1
Epoch 4
Participant flow — Epoch 4
MilestoneStudy Participants
Started70
Completed67
Not completed3
Withdrew: Physician decision1
Withdrew: Withdrawal by subject2

Outcome measures

PrimaryRate of Acute Serious Bacterial Infections Per Year (ASBI)

Annual rate of validated acute serious bacterial infections was calculated using a Poisson model to account for the different lengths of observation per participant. The observation period for each participant starts with the day of the first subcutaneous (SC) infusion in Study Epoch 2 and ends with the day of the End of Study visit.

Time frame:
1 year
Reported as:
Number · Estimated infections/ year
Rate of Acute Serious Bacterial Infections Per Year (ASBI)
Estimated infections/ yearStudy Participants
Rate of Acute Serious Bacterial Infections Per Year (ASBI)0.012
Statistical analysis
  • Study Participants · Poisson · p = <0.0001 · Poisson: 0.012
SecondaryAnnual Rate of All Infections Per Participant
Time frame:
1 year
Reported as:
Number · Estimated infections/year
Annual Rate of All Infections Per Participant
Estimated infections/yearIntravenous 10% - Epoch 1Subcutaneous 20% - Epochs 2 Thru 4
Annual Rate of All Infections Per Participant3.86 (2.77 to 5.22)2.41 (1.89 to 3.03)
SecondaryAnnual Rate of Sinus Infections Per Participant
Time frame:
1 year
Reported as:
Number · Estimated infections/year
Annual Rate of Sinus Infections Per Participant
Estimated infections/yearIntravenous 10% - Epoch 1Subcutaneous 20% - Epochs 2 Thru 4
Annual Rate of Sinus Infections Per Participant0.97 (0.61 to 1.45)0.69 (0.50 to 0.93)
SecondaryAnnual Rate of Fever Episodes Per Participant
Time frame:
1 year
Reported as:
Number · Estimated episodes/year
Annual Rate of Fever Episodes Per Participant
Estimated episodes/yearIntravenous 10% - Epoch 1Subcutaneous 20% - Epochs 2 Thru 4
Annual Rate of Fever Episodes Per Participant0.61 (0.34 to 0.99)0.13 (0.08 to 0.21)
SecondaryAnnual Rate of Days Off School/Work or Days Unable to Perform Normal Daily Activities Due to Illness or Infection Per Participant
Time frame:
1 year
Reported as:
Number · Estimated days off/participant
Annual Rate of Days Off School/Work or Days Unable to Perform Normal Daily Activities Due to Illness or Infection Per Participant
Estimated days off/participantIntravenous 10% - Epoch 1Subcutaneous 20% - Epochs 2 Thru 4
Annual Rate of Days Off School/Work or Days Unable to Perform Normal Daily Activities Due to Illness or Infection Per Participant3.20 (1.88 to 5.03)1.16 (0.70 to 1.79)
SecondaryAnnual Rate of Days on Antibiotics Per Participant
Time frame:
1 year
Reported as:
Number · Estimated days/particpant
Annual Rate of Days on Antibiotics Per Participant
Estimated days/particpantIntravenous 10% - Epoch 1Subcutaneous 20% - Epochs 2 Thru 4
Annual Rate of Days on Antibiotics Per Participant63.20 (43.39 to 88.29)57.59 (40.71 to 78.59)
SecondaryAnnual Rate of Hospitalizations for Illness or Infection Per Participant
Time frame:
1 year
Reported as:
Number · Estimated hospitalizations/participant
Annual Rate of Hospitalizations for Illness or Infection Per Participant
Estimated hospitalizations/participantIntravenous 10% - Epoch 1Subcutaneous 20% - Epochs 2 Thru 4
Annual Rate of Hospitalizations for Illness or Infection Per Participant0.05 (0.02 to 0.10)0.02 (0.01 to 0.04)
SecondaryAnnual Rate of Days of Hospitalizations for Illness or Infection Per Participant
Time frame:
1 year
Reported as:
Number · Estimated days/participant
Annual Rate of Days of Hospitalizations for Illness or Infection Per Participant
Estimated days/participantIntravenous 10% - Epoch 1Subcutaneous 20% - Epochs 2 Thru 4
Annual Rate of Days of Hospitalizations for Illness or Infection Per Participant0.20 (0.08 to 0.42)0.11 (0.05 to 0.20)
SecondaryAnnual Rate of Acute (Urgent or Unscheduled) Physician Visits, or Visits to the Emergency Room for Illness or Infection Per Participant
Time frame:
1 year
Reported as:
Number · Estimated visits/participant
Annual Rate of Acute (Urgent or Unscheduled) Physician Visits, or Visits to the Emergency Room for Illness or Infection Per Participant
Estimated visits/participantIntravenous 10% - Epoch 1Subcutaneous 20% - Epochs 2 Thru 4
Annual Rate of Acute (Urgent or Unscheduled) Physician Visits, or Visits to the Emergency Room for Illness or Infection Per Participant1.73 (1.03 to 2.68)0.86 (0.54 to 1.28)
SecondaryBioavailability of IGSC, 20% as Measured by the Ratio of the Geometric Means of Immunoglobulin G (IgG) AUCSC (Epoch 4) to IgG AUCIV,0-τ (Standardized to 1 Week) (Epoch 1) Adjusted for Dose and Dosing Frequency (Participants ≥12 Years Old)

IGSC, 20% = Immune Globulin Subcutaneous (Human), 20% Solution; AUCSC = area under the concentration-time curve following subcutaneous administration; AUCIV,0-τ = area under the concentration-time curve following intravenous administration over a dosing interval

Time frame:
Epoch 1: 3 week IV administration interval: Week 10, 11, 12, 13. Epoch 1: 4 week IV interval: Week 9, 10, 11, 12, 13. Epoch 4 Subcutaneous administration weeks 17, 18
Reported as:
Geometric mean · Ratio
Bioavailability of IGSC, 20% as Measured by the Ratio of the Geometric Means of Immunoglobulin G (IgG) AUCSC (Epoch 4) to IgG AUCIV,0-τ (Standardized to 1 Week) (Epoch 1) Adjusted for Dose and Dosing Frequency (Participants ≥12 Years Old)
RatioStudy Epochs 1-4
Bioavailability of IGSC, 20% as Measured by the Ratio of the Geometric Means of Immunoglobulin G (IgG) AUCSC (Epoch 4) to IgG AUCIV,0-τ (Standardized to 1 Week) (Epoch 1) Adjusted for Dose and Dosing Frequency (Participants ≥12 Years Old)1.0855 (1.0394 to 1.1336)
SecondaryTrough Levels of IgG (Total), and IgG Subclasses at the End of the Treatment Intervals
Time frame:
Epoch 1: 3 week IV interval- weeks 0, 1, 4, 7, 10, 13. Epoch 1: 4 week IV interval- weeks 0, 1, 5, 9, 13. Epochs 2 & 3: Subcutaneous (SC) weeks 5, 9. Epoch 4: SC weeks 1, 9, 17, 29, 40 (week dependent on time to establish "Adjusted Dose" in Epoch 2)
Reported as:
Geometric mean · g/L
Trough Levels of IgG (Total), and IgG Subclasses at the End of the Treatment Intervals
g/LIV 10% 3 WeeksIV 10% 4 WeeksSC 20% 145% IV 1 WeekSC 20% Adjusted 1 WeekSC 20% Individualized 1 Week
Total IgG11.58 (10.36 to 12.94)10.19 (9.55 to 10.88)14.77 (13.86 to 15.74)14.20 (13.48 to 14.96)14.74 (14.03 to 15.48)
IgG Subclass 16.23 (5.47 to 7.09)5.45 (5.04 to 5.91)8.06 (7.51 to 8.65)7.83 (7.33 to 8.38)7.41 (6.98 to 7.87)
IgG Subclass 23.92 (3.53 to 4.35)3.30 (3.08 to 3.54)4.83 (4.47 to 5.21)4.95 (4.65 to 5.26)4.94 (4.69 to 5.20)
IgG Subclass 30.352 (0.285 to 0.435)0.405 (0.347 to 0.473)0.516 (0.463 to 0.574)0.514 (0.458 to 0.578)0.514 (0.456 to 0.580)
IgG Subclass 40.239 (0.202 to 0.281)0.186 (0.165 to 0.209)0.309 (0.273 to 0.350)0.304 (0.280 to 0.331)0.311 (0.289 to 0.335)
SecondaryTrough Levels of Anti-Tetanus Antibody
Time frame:
Epoch 1: 3 week IV interval- weeks 1, 4, 7, 10, 13. Epoch 1: 4 week IV interval- weeks 1, 5, 9, 13. Epochs 2 & 3: Subcutaneous (SC) weeks 5, 9. Epoch 4: SC weeks 1, 9, 17, 29, 40 (week dependent on time to establish "Adjusted Dose" in Epoch 2)
Reported as:
Geometric mean · IU/mL
Trough Levels of Anti-Tetanus Antibody
IU/mLOverall Study Arm
Pre-Study Medication- Epoch 1 Week 1 (N= 64)2.28 (1.84 to 2.82)
IV 10% 3 Weeks- Epoch 1 Week 4 (N= 15)3.36 (2.44 to 4.63)
IV 10% 3 Weeks- Epoch 1 Week 7 (N= 16)2.66 (2.04 to 3.48)
IV 10% 3 Weeks - Epoch 1 Week 10 (N= 19)2.55 (1.83 to 3.56)
IV 10% 3 Weeks- Epoch 1 Week 13 (N= 16)2.26 (1.52 to 3.37)
IV 10% 4 Weeks- Epoch 1 Week 5 (N= 46)1.92 (1.44 to 2.56)
IV 10% 4 Weeks- Epoch 1 Week 9 (N= 44)2.31 (1.79 to 2.96)
IV 10% 4 Weeks- Epoch 1 Week 13 (N= 43)2.28 (1.84 to 2.81)
SC 20% 145% IV 1 Week- Epoch 2 Week 5 (N= 29)4.08 (3.12 to 5.33)
SC 20% 145% IV 1 Week- Epoch 2 Week 9 (N= 27)4.49 (3.32 to 6.08)
SC 20% adjusted 1 Week- Epoch 3 Week 5 (N= 55)3.76 (3.21 to 4.40)
SC 20% adjusted 1 Week- Epoch 3 Week 9 (N= 58)3.09 (2.64 to 3.62)
SC 20% adjusted 1 Week- Epoch 4 Week 1 (N= 62)2.75 (2.39 to 3.17)
SC 20% individualized 1 Week Epoch 4 Week 9 (N=58)3.15 (2.73 to 3.63)
SC 20% individualized 1 Week Epoch 4 Week 17(N=51)3.17 (2.74 to 3.67)
SC 20% individualized 1 Week Epoch 4 Week 29(N=54)1.74 (1.48 to 2.03)
SC 20% individualized 1 Week- End of Study (N= 53)1.97 (1.66 to 2.32)
SecondaryTrough Levels of Anti-Haemophilus Influenza B Antibody
Time frame:
Epoch 1: 3 week IV interval- weeks 1, 4, 7, 10, 13. Epoch 1: 4 week IV interval- weeks 1, 5, 9, 13. Epochs 2 & 3: Subcutaneous (SC) weeks 5, 9. Epoch 4: SC weeks 1, 9, 17, 29, 40 (week dependent on time to establish "Adjusted Dose" in Epoch 2)
Reported as:
Geometric mean · mg/L
Trough Levels of Anti-Haemophilus Influenza B Antibody
mg/LOverall Study Arm
Pre-Study Medication- Epoch 1 Week 1 (N= 65)2.91 (2.55 to 3.34)
IV 10% 3 Weeks- Epoch 1 Week 4 (N= 15)2.71 (2.07 to 3.56)
IV 10% 3 Weeks- Epoch 1 Week 7 (N= 16)3.08 (2.36 to 4.01)
IV 10% 3 Weeks- Epoch 1 Week 10 (N= 19)2.42 (1.75 to 3.36)
IV 10% 3 Weeks- Epoch 1 Week 13 (N= 14)2.47 (1.85 to 3.29)
IV 10% 4 Weeks- Epoch 1 Week 5 (N= 45)2.82 (2.30 to 3.46)
IV 10% 4 Weeks- Epoch 1 Week 9 (N= 44)2.71 (2.23 to 3.30)
IV 10% 4 Weeks- Epoch 1 Week 13 (N= 43)2.74 (2.20 to 3.42)
SC 20% 145% IV 1 Week- Epoch 2 Week 5 (N= 29)4.07 (3.44 to 4.83)
SC 20% 145% IV 1 Week- Epoch 2 Week 9 (N= 27)3.94 (3.30 to 4.71)
SC 20% adjusted 1 Week- Epoch 3 Week 5 (N= 56)3.59 (3.12 to 4.14)
SC 20% adjusted 1 Week- Epoch 3 Week 9 (N= 58)3.62 (3.10 to 4.22)
SC 20% adjusted 1 Week- Epoch 4 Week 1 (N= 62)3.47 (3.06 to 3.94)
SC 20% individualized 1 Week Epoch 4 Week 9 (N=58)4.35 (3.87 to 4.89)
SC 20% individualized 1 Week Epoch 4 Week 17(N=51)4.76 (4.21 to 5.39)
SC 20% individualized 1 Week Epoch 4 Week 29(N=54)4.06 (3.55 to 4.65)
SC 20% individualized 1 Week- End of Study (N= 52)5.07 (4.48 to 5.73)
SecondaryTrough Levels of Anti-Hepatitis B Antibody
Time frame:
Epoch 1: 3 week IV interval- weeks 1, 4, 7, 10, 13. Epoch 1: 4 week IV interval- weeks 1, 5, 9, 13. Epochs 2 & 3: Subcutaneous (SC) weeks 5, 9. Epoch 4: SC weeks 1, 9, 17, 29, 40 (week dependent on time to establish "Adjusted Dose" in Epoch 2)
Reported as:
Geometric mean · mIU/mL
Trough Levels of Anti-Hepatitis B Antibody
mIU/mLStudy Epochs 1-4
Pre-Study Medication- Epoch 1 Week 1 (N= 66)266.6 (232.3 to 305.9)
IV 10% 3 Weeks- Epoch 1 Week 4 (N= 15)357.8 (312.2 to 410.1)
IV 10% 3 Weeks- Epoch 1 Week 7 (N= 17)402.6 (333.4 to 486.0)
IV 10% 3 Weeks- Epoch 1 Week 10 (N= 19)376.6 (315.7 to 449.3)
IV 10% 3 Weeks- Epoch 1 Week 13 (N= 16)392.2 (310.4 to 495.6)
IV 10% 4 Weeks- Epoch 1 Week 5 (N= 45)301.1 (266.2 to 340.5)
IV 10% 4 Weeks- Epoch 1 Week 9 (N= 44)304.0 (271.0 to 341.0)
IV 10% 4 Weeks- Epoch 1 Week 13 (N= 43)296.3 (266.0 to 330.2)
SC 20% 145% IV 1 Week- Epoch 2 Week 5 (N= 29)463.7 (425.0 to 506.0)
SC 20% 145% IV 1 Week- Epoch 2 Week 9 (N= 27)525.0 (478.1 to 576.5)
SC 20% adjusted 1 Week- Epoch 3 Week 5 (N= 57)581.9 (533.4 to 634.9)
SC 20% adjusted 1 Week- Epoch 3 Week 9 (N= 58)622.4 (579.8 to 668.1)
SC 20% adjusted 1 Week- Epoch 4 Week 1 (N= 62)552.8 (509.7 to 599.6)
SC 20% individualized 1 Week Epoch 4 Week 9(N= 58)434.4 (400.4 to 471.2)
SC 20% individualized 1 Week Epoch 4 Week 17(N=53)444.5 (408.2 to 484.1)
SC 20% individualized 1 Week Epoch 4 Week 29(N=54)389.2 (355.9 to 425.7)
SC 20% individualized 1 Week- End of Study (N=56)403.1 (371.7 to 437.1)
SecondaryPharmacokinetics Parameters for Immunoglobulin G (IgG): Area Under the Curve (AUC)

The AUC between adjacent infusions will be calculated by the trapezoidal rule. Linear interpolation/extrapolation will be used to calculate the AUC for exact duration of the infusion intervals (21 or 28 days for IV administration and 7 days for SC administration). To allow for comparisons between Epochs 1, 2 and 4, AUC0-τ will be standardized for the infusion intervals (3 or 4 weeks vs. 1 week)

Time frame:
Epoch 1: 3 week IV interval: Weeks 10-13. Epoch 1: 4 week IV interval: Weeks 9-13. Epoch 2: Subcutaneous (SC) weeks 9-10. Epoch 4: SC weeks 17-18
Reported as:
Geometric mean · g*days/L
Pharmacokinetics Parameters for Immunoglobulin G (IgG): Area Under the Curve (AUC)
g*days/LStudy Epoch 1: IGIV 10% Every 3 WeeksStudy Epoch 1: IGIV 10% Every 4 WeeksStudy Epoch 2: IGSC 20 %, 145 % of IGIV 10 %Study Epoch 4: IGSC 20 %, Individualized Dose
Pharmacokinetics Parameters for Immunoglobulin G (IgG): Area Under the Curve (AUC)352.05 (319.74 to 387.63)410.40 (381.24 to 441.79)108.33 (97.60 to 120.24)115.21 (109.23 to 121.52)
SecondaryPharmacokinetics Parameters for Immunoglobulin G (IgG): Dose Per Weight-adjusted Area Under the Curve (AUC)

The AUC between adjacent infusions will be calculated by the trapezoidal rule. Linear interpolation/extrapolation will be used to calculate the AUC for exact duration of the infusion intervals (21 or 28 days for IV administration and 7 days for SC administration). To allow for comparisons between Epochs 1, 2 and 4, AUC0-τ will be standardized for the infusion intervals (3 or 4 weeks vs. 1 week) adjusted for the dose per weight.

Time frame:
Epoch 1: 3 week IV interval: Weeks 10-13. Epoch 1: 4 week IV interval: Weeks 9-13. Epoch 2: Subcutaneous (SC) weeks 9-10. Epoch 4: SC weeks 17-18
Reported as:
Geometric mean · (g*days/L)/(g/kg)
Pharmacokinetics Parameters for Immunoglobulin G (IgG): Dose Per Weight-adjusted Area Under the Curve (AUC)
(g*days/L)/(g/kg)Study Epoch 1: IGIV 10% Every 3 WeeksStudy Epoch 1: IGIV 10% Every 4 WeeksStudy Epoch 2: IGSC 20 %, 145 % of IGIV 10 %Study Epoch 4: IGSC 20 %, Individualized Dose
Pharmacokinetics Parameters for Immunoglobulin G (IgG): Dose Per Weight-adjusted Area Under the Curve (AUC)606.99 (495.29 to 743.87)796.30 (715.36 to 886.40)472.50 (411.07 to 543.10)536.05 (495.58 to 579.82)
SecondaryPharmacokinetics Parameters for Immunoglobulin G (IgG): Clearance (CL) for Immune Globulin Administered Intravenously (IGIV) and Apparent Clearance for Immune Globulin Administered Subcutaneously (IGSC)

Clearance (CL) or apparent clearance (CL/F) for IV and SC administration, respectively, will be determined by the formula: CL or CL/F = (Dose (mg/kg)) / (AUC 0-τ). (F= bioavailability)

Time frame:
Epoch 1: 3 week IV interval: Weeks 10-13. Epoch 1: 4 week IV interval: Weeks 9-13. Epoch 2: Subcutaneous (SC) weeks 9-10. Epoch 4: SC weeks 17-18
Reported as:
Geometric mean · mL/kg/days
Pharmacokinetics Parameters for Immunoglobulin G (IgG): Clearance (CL) for Immune Globulin Administered Intravenously (IGIV) and Apparent Clearance for Immune Globulin Administered Subcutaneously (IGSC)
mL/kg/daysStudy Epoch 1: IGIV 10% Every 3 WeeksStudy Epoch 1: IGIV 10% Every 4 WeeksStudy Epoch 2: IGSC 20 %, 145 % of IGIV 10 %Study Epoch 4: IGSC 20 %, Individualized Dose
Pharmacokinetics Parameters for Immunoglobulin G (IgG): Clearance (CL) for Immune Globulin Administered Intravenously (IGIV) and Apparent Clearance for Immune Globulin Administered Subcutaneously (IGSC)1.65 (1.34 to 2.02)1.26 (1.13 to 1.40)2.12 (1.84 to 2.43)1.87 (1.72 to 2.02)
SecondaryPharmacokinetics Parameters for Immunoglobulin G (IgG): Maximum Concentration (Cmax)

The maximum concentration (Cmax) following administration of study drug (either immune globulin administered intravenously (IGIV) or immune globulin administered subcutaneously (IGSC).

Time frame:
Epoch 1: 3 week IV interval: Weeks 10-13. Epoch 1: 4 week IV interval: Weeks 9-13. Epoch 2: Subcutaneous (SC) weeks 9-10. Epoch 4: SC weeks 17-18
Reported as:
Geometric mean · g/L
Pharmacokinetics Parameters for Immunoglobulin G (IgG): Maximum Concentration (Cmax)
g/LStudy Epoch 1: IGIV 10% Every 3 WeeksStudy Epoch 1: IGIV 10% Every 4 WeekStudy Epoch 2: IGSC 20 %, 145 % of IGIV 10 %Study Epoch 4: IGSC 20 %, Individualized Dose
Pharmacokinetics Parameters for Immunoglobulin G (IgG): Maximum Concentration (Cmax)27.09 (24.30 to 30.19)24.85 (23.18 to 26.64)17.31 (15.11 to 19.82)19.31 (18.13 to 20.57)
SecondaryPharmacokinetics Parameters for Immunoglobulin G (IgG): Time to Maximum Concentration (Tmax)

The minimum time (Tmax) to reach the maximum concentration (Cmax)

Time frame:
Epoch 1: 3 week IV interval: Weeks 10-13. Epoch 1: 4 week IV interval: Weeks 9-13. Epoch 2: Subcutaneous (SC) weeks 9-10. Epoch 4: SC weeks 17-18
Reported as:
Geometric mean · hours (h)
Pharmacokinetics Parameters for Immunoglobulin G (IgG): Time to Maximum Concentration (Tmax)
hours (h)Study Epoch 1: IGIV 10% Every 3 WeeksStudy Epoch 1: IGIV 10% Every 4 WeeksStudy Epoch 2: IGSC 20 %, 145 % of IGIV 10 %Study Epoch 4: IGSC 20 %, Individualized Dose
Pharmacokinetics Parameters for Immunoglobulin G (IgG): Time to Maximum Concentration (Tmax)6.94 (3.96 to 12.17)5.84 (3.62 to 9.40)54.19 (36.28 to 80.92)78.68 (65.37 to 94.70)
SecondaryPharmacokinetics Parameters for Immunoglobulin G (IgG): Minimum Concentration (Cmin)

The minimum concentration (Cmax) following administration of study drug (either immune globulin administered intravenously (IGIV) or immune globulin administered subcutaneously (IGSC).

Time frame:
Epoch 1: 3 week IV interval: Weeks 10-13. Epoch 1: 4 week IV interval: Weeks 9-13. Epoch 2: Subcutaneous (SC) weeks 9-10. Epoch 4: SC weeks 17-18
Reported as:
Geometric mean · g/L
Pharmacokinetics Parameters for Immunoglobulin G (IgG): Minimum Concentration (Cmin)
g/LStudy Epoch 1: IGIV 10% Every 3 WeeksStudy Epoch 1: IGIV 10% Every 4 WeeksStudy Epoch 2: IGSC 20 %, 145 % of IGIV 10 %Study Epoch 4: IGSC 20 %, Individualized Dose
Pharmacokinetics Parameters for Immunoglobulin G (IgG): Minimum Concentration (Cmin)12.03 (10.64 to 13.60)10.37 (9.50 to 11.33)13.85 (12.61 to 15.21)14.00 (13.14 to 14.91)
SecondaryPharmacokinetics Parameters for Haemophilus Influenza B Antibody: Area Under the Curve (AUC)

The AUC between adjacent infusions will be calculated by the trapezoidal rule . Linear interpolation/extrapolation will be used to calculate the AUC for exact duration of the infusion intervals (21 or 28 days for IV administration and 7 days for SC administration). To allow for comparisons between Epochs 1, 2 and 4, AUC 0-τ will be standardized for the infusion intervals (3 or 4 weeks vs. 1 week )

Time frame:
Epoch 1: 3 week IV interval: Weeks 10-13. Epoch 1: 4 week IV interval: Weeks 9-13. Epoch 2: Subcutaneous (SC) weeks 9-10. Epoch 4: SC weeks 17-18
Reported as:
Geometric mean · mg*days/L
Pharmacokinetics Parameters for Haemophilus Influenza B Antibody: Area Under the Curve (AUC)
mg*days/LStudy Epoch 1: IGIV 10% Every 3 WeeksStudy Epoch 1: IGIV 10% Every 4 WeeksStudy Epoch 2: IGSC 20 %, 145 % of IGIV 10 %Study Epoch 4: IGSC 20 %, Individualized Dose
Pharmacokinetics Parameters for Haemophilus Influenza B Antibody: Area Under the Curve (AUC)80.79 (65.58 to 99.53)123.05 (93.36 to 162.18)29.51 (23.25 to 37.46)30.64 (26.29 to 35.72)
SecondaryPharmacokinetics Parameters for Haemophilus Influenza B Antibody: Dose Per Weight-adjusted Area Under the Curve (AUC)

The AUC between adjacent infusions will be calculated by the trapezoidal rule . Linear interpolation/extrapolation will be used to calculate the AUC for exact duration of the infusion intervals (21 or 28 days for IV administration and 7 days for SC administration). To allow for comparisons between Epochs 1, 2 and 4, AUC 0-τ will be standardized for the infusion intervals (3 or 4 weeks vs. 1 week) adjusted for the dose per weight.

Time frame:
Epoch 1: 3 week IV interval: Weeks 10-13. Epoch 1: 4 week IV interval: Weeks 9-13. Epoch 2: Subcutaneous (SC) weeks 9-10. Epoch 4: SC weeks 17-18
Reported as:
Geometric mean · (mg*days/L)/(g/kg)
Pharmacokinetics Parameters for Haemophilus Influenza B Antibody: Dose Per Weight-adjusted Area Under the Curve (AUC)
(mg*days/L)/(g/kg)Study Epoch 1: IGIV 10% Every 3 WeeksStudy Epoch 1: IGIV 10% Every 4 WeeksStudy Epoch 2: IGSC 20 %, 145 % of IGIV 10 %Study Epoch 4: IGSC 20 %, Individualized Dose
Pharmacokinetics Parameters for Haemophilus Influenza B Antibody: Dose Per Weight-adjusted Area Under the Curve (AUC)139.29 (110.89 to 174.97)239.99 (181.92 to 316.61)128.72 (96.65 to 171.42)141.78 (121.75 to 165.12)
SecondaryPharmacokinetics Parameters for Haemophilus Influenza B Antibody: Clearance (CL) for Immune Globulin Administered Intravenously (IGIV) and Apparent Clearance (CL/F) for Immune Globulin Administered Subcutaneously

Clearance (CL) or apparent clearance (CL/F) for IV and SC administration, respectively, will be determined by the formula: CL or CL/F = (Dose (mg/kg)) / (AUC 0- τ). (F= bioavailability)

Time frame:
Epoch 1: 3 week IV interval: Weeks 10-13. Epoch 1: 4 week IV interval: Weeks 9-13. Epoch 2: Subcutaneous (SC) weeks 9-10. Epoch 4: SC weeks 17-18
Reported as:
Geometric mean · mL/kg/days
Pharmacokinetics Parameters for Haemophilus Influenza B Antibody: Clearance (CL) for Immune Globulin Administered Intravenously (IGIV) and Apparent Clearance (CL/F) for Immune Globulin Administered Subcutaneously
mL/kg/daysStudy Epoch 1: IGIV 10% Every 3 WeeksOverall Study ArmStudy Epoch 1: IGIV 10% Every 4 WeeksStudy Epoch 2: IGSC 20%, 145% of IGIV 10%Study Epoch 4: IGSC 20%, Individualized Dose
Pharmacokinetics Parameters for Haemophilus Influenza B Antibody: Clearance (CL) for Immune Globulin Administered Intravenously (IGIV) and Apparent Clearance (CL/F) for Immune Globulin Administered Subcutaneously7.18 (5.72 to 9.02)4.17 (3.16 to 5.50)7.77 (5.83 to 10.35)7.05 (6.06 to 8.21)
SecondaryPharmacokinetics Parameters for Haemophilus Influenza B Antibody: Maximum Concentration (Cmax)

The maximum concentration (Cmax) following administration of study drug (either immune globulin administered intravenously (IGIV) or immune globulin administered subcutaneously (IGSC).

Time frame:
Epoch 1: 3 week IV interval: Weeks 10-13. Epoch 1: 4 week IV interval: Weeks 9-13. Epoch 2: Subcutaneous (SC) weeks 9-10. Epoch 4: SC weeks 17-18
Reported as:
Geometric mean · mg/L
Pharmacokinetics Parameters for Haemophilus Influenza B Antibody: Maximum Concentration (Cmax)
mg/LStudy Epoch 1: IGIV 10% Every 3 WeeksStudy Epoch 1: IGIV 10% Every 4 WeeksStudy Epoch 2: IGSC 20%, 145% of IGIV 10%Study Epoch 4: IGSC 20 %, Individualized Dose
Pharmacokinetics Parameters for Haemophilus Influenza B Antibody: Maximum Concentration (Cmax)6.31 (5.25 to 7.59)7.22 (5.75 to 9.05)4.40 (3.45 to 5.62)4.86 (4.16 to 5.68)
SecondaryPharmacokinetics Parameters for Haemophilus Influenza B Antibody: Time to Maximum Concentration (Tmax)

The minimum time (Tmax) to reach the maximum concentration (Cmax)

Time frame:
Epoch 1: 3 week IV interval: Weeks 10-13. Epoch 1: 4 week IV interval: Weeks 9-13. Epoch 2: Subcutaneous (SC) weeks 9-10. Epoch 4: SC weeks 17-18
Reported as:
Geometric mean · Hours (s)
Pharmacokinetics Parameters for Haemophilus Influenza B Antibody: Time to Maximum Concentration (Tmax)
Hours (s)Study Epoch 1: IGIV 10% Every 3 WeeksStudy Epoch 1: IGIV 10% Every 4 WeeksStudy Epoch 2: IGSC 20 %, 145 % of IGIV 10 %Study Epoch 4: IGSC 20 %, Individualized Dose
Pharmacokinetics Parameters for Haemophilus Influenza B Antibody: Time to Maximum Concentration (Tmax)3.11 (2.69 to 3.59)3.71 (2.69 to 5.12)70.67 (51.14 to 97.66)66.87 (56.22 to 79.53)
SecondaryPharmacokinetics Parameters for Haemophilus Influenza B Antibody: Minimum Concentration (Cmin)

The minimum concentration (Cmax) following administration of study drug (either immune globulin administered intravenously (IGIV) or immune globulin administered subcutaneously (IGSC).

Time frame:
Epoch 1: 3 week IV interval: Weeks 10-13. Epoch 1: 4 week IV interval: Weeks 9-13. Epoch 2: Subcutaneous (SC) weeks 9-10. Epoch 4: SC weeks 17-18
Reported as:
Median · mg/L
Pharmacokinetics Parameters for Haemophilus Influenza B Antibody: Minimum Concentration (Cmin)
mg/LStudy Epoch 1: IGIV 10% Every 3 WeeksStudy Epoch 1: IGIV 10% Every 4 WeeksStudy Epoch 2: IGSC 20%, 145% of IGIV 10%Study Epoch 4: IGSC 20%, Individualized Dose
Pharmacokinetics Parameters for Haemophilus Influenza B Antibody: Minimum Concentration (Cmin)2.82 (2.20 to 3.61)3.13 (2.31 to 4.26)3.97 (3.14 to 5.01)3.71 (3.15 to 4.37)
SecondaryCorrection Factor to Determine the Individually Adapted Dose in Study 170904 Epoch 4 (Dose Adjustment Table)

There is a high degree of variability in catabolism of immunoglobulin G (IgG) between individuals. To address this, trough levels immediately prior to the 9th weekly infusion in Epoch 3 were measured. The ratio of the measured trough levels on subcutaneous (SC) (Epoch 3) and intravenous (IV) administration (Epoch1) were compared to the expected trough level determined in Epoch 2. This was used to determine the Individually Adapted Dose to be used in Epoch 4. This was an interim study analysis.

Time frame:
29 weeks
Reported as:
Number · Correction factor
Correction Factor to Determine the Individually Adapted Dose in Study 170904 Epoch 4 (Dose Adjustment Table)
Correction factorCorrection Factor
Trough Level Ratio: 0.93 or more1.16
Trough Level Ratio: 0.941.14
Trough Level Ratio: 0.95 to 0.961.12
Trough Level Ratio: 0.97 to 0.981.11
Trough Level Ratio: 0.99 to 1.011.10
Trough Level Ratio: 1.02 to 1.041.09
Trough Level Ratio: 1.05 to 1.081.08
Trough Level Ratio: 1.09 to 1.131.07
Trough Level Ratio: 1.14 to 1.191.06
Trough Level Ratio: 1.20 to 1.261.05
Trough Level Ratio: 1.27 to 1.331.04
Trough Level Ratio: 1.34 to 1.401.03
Trough Level Ratio: 1.41 to 1.471.02
Trough Level Ratio: 1.48 to 1.551.01
Trough Level Ratio: 1.56 to 1.631.00
SecondaryNumber of Serious (SAEs) and Non-serious Adverse Events (AEs) (Including and Excluding Infections) Deemed Related to the Investigational Product Per Participant

Number of related SAEs and AEs divided by number of participants

Time frame:
Up to 20 months per subject (throughout entire study)
Reported as:
Number · Adverse events per participant
Number of Serious (SAEs) and Non-serious Adverse Events (AEs) (Including and Excluding Infections) Deemed Related to the Investigational Product Per Participant
Adverse events per participantINTRAVENOUS 10%SUBCUTANEOUS 20%
Non-SAEs - Including infections1.0392.122
Non-SAEs - Excluding infections1.0392.122
SAEs - Including infections0.0130
SAEs - Excluding infections0.0130
SecondaryNumber of Serious (SAEs) and Non-serious Adverse Events (AEs) (Including and Excluding Infections) Deemed Related to the Investigational Product Per Infusion

Number of related SAEs and AEs divided by number of subjects and divided by number of infusions

Time frame:
Up to 20 months per subject (throughout entire study)
Reported as:
Number · Adverse events per infusion
Number of Serious (SAEs) and Non-serious Adverse Events (AEs) (Including and Excluding Infections) Deemed Related to the Investigational Product Per Infusion
Adverse events per infusionINTRAVENOUS 10%SUBCUTANEOUS 20%
Non-SAEs - Including Infections0.2470.036
Non-SAEs -Excluding Infections0.2470.036
SAEs - Including Infections0.0030
SAEs -Excluding Infections0.0030
SecondaryNumber of Serious (SAEs) and Non-serious Adverse Events (AEs) (Including and Excluding Infections) Regardless of Relationship to the Investigational Product Per Participant

Number of all SAEs and AEs divided by number of participants

Time frame:
Up to 20 months per subject (throughout entire study)
Reported as:
Number · Adverse events per participant
Number of Serious (SAEs) and Non-serious Adverse Events (AEs) (Including and Excluding Infections) Regardless of Relationship to the Investigational Product Per Participant
Adverse events per participantINTRAVENOUS 10%SUBCUTANEOUS 20%
Non-SAEs - Including infections3.3259.014
Non-SAEs - Excluding infections2.3386.297
SAEs - Including infections0.0130.027
SAEs - Excluding infections0.0130.014
SecondaryNumber of Serious (SAEs) and Non-serious Adverse Events (AEs) (Including and Excluding Infections) Regardless of Relationship to the Investigational Product Per Infusion

Number of all SAEs and AEs divided by number of infusions

Time frame:
Up to 20 months per subject (throughout entire study)
Reported as:
Number · Adverse events per infusion
Number of Serious (SAEs) and Non-serious Adverse Events (AEs) (Including and Excluding Infections) Regardless of Relationship to the Investigational Product Per Infusion
Adverse events per infusionIGIV, 10%Subcutaneous, 20%
Non-SAEs - Including infections0.3900.114
Non-SAEs - Excluding infections0.2960.079
SAEs - including infections0.0030.000
SAEs - Excluding infections0.0030.000
SecondaryNumber of Adverse Events (AEs) (Including and Excluding Infections) That Begin During or Within 72 Hours of Completion of Infusion Per Participant

Number of AEs that begin during or within 72 hours of completion of infusion divided by number of participants

Time frame:
Within 72 hours of completion of infusion
Reported as:
Number · Adverse events per participant
Number of Adverse Events (AEs) (Including and Excluding Infections) That Begin During or Within 72 Hours of Completion of Infusion Per Participant
Adverse events per participantIntravenous 10%Subcutaneous 20%
Non-SAEs - Including infections1.3774.581
Non-SAEs - Excluding infections1.2603.703
SAEs - Including infections0.0130
SAEs - Excluding infections0.0130
SecondaryNumber of Adverse Events (AEs) (Including and Excluding Infections) That Begin During or Within 72 Hours of Completion of Infusion Per Infusion

Number of AEs that begin during or within 72 hours of completion of infusion divided by the number of infusions

Time frame:
Within 72 hours of completion of infusion
Reported as:
Number · Adverse events per infusion
Number of Adverse Events (AEs) (Including and Excluding Infections) That Begin During or Within 72 Hours of Completion of Infusion Per Infusion
Adverse events per infusionIntravenous 10%Subcutaneous 20%
Non-SAEs - Including infections0.3270.078
Non-SAEs - Excluding infections0.2990.063
SAEs - Including infections0.0030
SAEs - Excluding infections0.0030
SecondaryNumber of Adverse Events (AEs) (Including and Excluding Infections) That Begin During or Within 24 Hours of Completion of Infusion Per Participant

Number of AEs that begin during or within 24 hours of completion of infusion divided by number of participants

Time frame:
Within 24 hours of completion of infusion
Reported as:
Number · Adverse events per participant
Number of Adverse Events (AEs) (Including and Excluding Infections) That Begin During or Within 24 Hours of Completion of Infusion Per Participant
Adverse events per participantIntravenous 10%Subcutaneous 20%
Non-SAEs - Including infections0.9613.365
Non-SAEs - Excluding infections0.9483.027
SAEs - Including infections00
SAEs - Excluding infections00
SecondaryNumber of Adverse Events (AEs) (Including and Excluding Infections) That Begin During or Within 24 Hours of Completion of Infusion Per Infusion

Number of AEs that begin during or within 24 hours of completion of infusion divided by number of infusions

Time frame:
Within 24 hours of completion of infusion
Reported as:
Number · Adverse events per infusion
Number of Adverse Events (AEs) (Including and Excluding Infections) That Begin During or Within 24 Hours of Completion of Infusion Per Infusion
Adverse events per infusionIntravenous 10%Subcutaneous 20%
Non-SAEs - Including infections0.2280.058
Non-SAEs - Excluding infections0.2250.052
SAEs - Including infections00
SAEs - Excluding infections00
SecondaryNumber of Adverse Events (AEs) (Including and Excluding Infections) That Begin During or Within 1 Hour of Completion of Infusion Per Participant

Number of AEs that begin during or within 1 hour of completion of infusion divided by number of participants

Time frame:
Within 1 hour of completion of infusion
Reported as:
Number · Adverse events per participant
Number of Adverse Events (AEs) (Including and Excluding Infections) That Begin During or Within 1 Hour of Completion of Infusion Per Participant
Adverse events per participantIntravenous 10%Subcutaneous 20%
Non-SAEs - Including infections0.6621.865
Non-SAEs - Excluding infections0.6621.797
SAEs - Including infections00
SAEs - Excluding infections00
SecondaryNumber of Adverse Events (AEs) (Including and Excluding Infections) That Begin During or Within 1 Hour of Completion of Infusion

Number of AEs that begin during or within 1 hour of completion of infusion divided by number of infusions

Time frame:
Within 1 hour of completion of infusion
Reported as:
Number · Adverse events per infusion
Number of Adverse Events (AEs) (Including and Excluding Infections) That Begin During or Within 1 Hour of Completion of Infusion
Adverse events per infusionIntravenous 10%Subcutaneous 20%
Non-SAEs - Including infections0.1570.032
Non-SAEs - Excluding infections0.1570.031
SAEs - Including infections00
SAEs - Excluding infections00
SecondaryCausally Related and/or Temporally Associated Adverse Events (AEs) Per Infusion

The total number of all AEs (including and excluding infections) that begin during infusion or within 72 hours of completion of an infusion ("temporally associated") plus the total number of AEs (including and excluding infections) starting more than 72 hours following the completion of an infusion determined by the investigator to be at least possibly related to the study drug("related"), divided by the total number of infusions

Time frame:
Within 72 hours post infusion for Temporally Associated AEs; End of each Study Epoch (Epoch 1, Epoch 2, Epoch 3, and Epoch 4) for Causally Related AEs
Reported as:
Number · Adverse events per infusion
Causally Related and/or Temporally Associated Adverse Events (AEs) Per Infusion
Adverse events per infusionIntravenous 10%Subcutaneous 20%
Non-SAEs - Including infections0.3360.079
Non-SAEs - Excluding infections0.3090.064
SAEs - Including infections0.0030
SAEs - Excluding infections0.0030
SecondaryPercentage of Infusions Associated With One or More Local Non-serious Adverse Events (Non-SAEs)

The number of infusions associated with local non-SAEs divided by the total number of infusions.

Time frame:
Up to 20 months (throughout entire study)
Reported as:
Number · Percent of infusions
Percentage of Infusions Associated With One or More Local Non-serious Adverse Events (Non-SAEs)
Percent of infusionsIntravenous 10%Subcutaneous 20%
Percentage of Infusions Associated With One or More Local Non-serious Adverse Events (Non-SAEs)0.91.8
SecondaryPercentage of Participants Reporting One or More Local Non-serious Adverse Events (Non-SAEs)
Time frame:
Up to 20 months (throughout entire study)
Reported as:
Number · Percent of participants
Percentage of Participants Reporting One or More Local Non-serious Adverse Events (Non-SAEs)
Percent of participantsIntravenous 10%Subcutaneous 20%
Percentage of Participants Reporting One or More Local Non-serious Adverse Events (Non-SAEs)3.931.1
SecondaryNumber of Infusions for Which the Infusion Rate Was Reduced and/or the Infusion Was Interrupted or Stopped Due to Tolerability Concerns or AEs
Time frame:
Up to 20 months (throughout entire study)
Reported as:
Number · Infusions
Number of Infusions for Which the Infusion Rate Was Reduced and/or the Infusion Was Interrupted or Stopped Due to Tolerability Concerns or AEs
InfusionsIntravenous 10%Subcutaneous 20%
Infusion rate reduced45
Infusion interrupted52
Infusion stopped01
SecondaryPercentage of Participants for Whom the Infusion Rate Was Reduced and/or the Infusion Was Interrupted or Stopped Due to Tolerability Concerns or AEs
Time frame:
Up to 20 months (throughout entire study)
Reported as:
Number · Percent of participants
Percentage of Participants for Whom the Infusion Rate Was Reduced and/or the Infusion Was Interrupted or Stopped Due to Tolerability Concerns or AEs
Percent of participantsIntravenous 10%Subcutaneous 20%
Infusion rate reduced1.35.4
Infusion interrupted6.51.4
Infusion stopped0.01.4
SecondaryPercentage of Infusions Tolerated With Intravenous or Subcutaneous Administration

An infusion will be deemed as tolerated unless one of the following occurs: 1. Any serious related AE(s) 2. Any non-serious local or systemic related AE(s) that prevent(s) completion of infusion 3. Any severe non-serious local or systemic related AE(s) that occur within 60 minutes of completion of the infusion

Time frame:
Up to 20 months (throughout entire study)
Reported as:
Number · Percent of infusions
Percentage of Infusions Tolerated With Intravenous or Subcutaneous Administration
Percent of infusionsIntravenous 10%Subcutaneous 20%
Percentage of Infusions Tolerated With Intravenous or Subcutaneous Administration100100
SecondaryShort Term Tolerance - Change in Systolic Blood Pressure: Immune Globulin Administered Intravenously (Human), 10% (IV 10%), Infusion 1

Vital signs measured pre-infusion, during infusion, and post-infusion of Immune globulin administered intravenously (Human), 10% (IV 10%) was graded by the investigator and the sponsor using a 4-grade scale: mild (grade 1), moderate (grade 2), severe (grade 3) or life-threatening (grade 4) according to the U.S. Department of Health and Human Services, Food and Drug Administration, Center for Biologics Evaluation and Research; Guidance for Industry - Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials, September2007. \*Note 5th Grade (grade 0) added to scale to reflect within normal range.

Time frame:
Within 30 minutes pre-infusion, during infusion and within 30 minutes post infusion
Reported as:
Count of participants · Participants
Short Term Tolerance - Change in Systolic Blood Pressure: Immune Globulin Administered Intravenously (Human), 10% (IV 10%), Infusion 1
ParticipantsPre-Infusion Toxicity Grade 0Pre-Infusion Toxicity Grade 1Pre-Infusion Toxicity Grade 2Pre-Infusion Toxicity Grade 3Pre-Infusion Toxicity Grade 4
Maximum Post-Infusion Grade 0611100
Maximum Post-Infusion Grade 1101100
Maximum Post-Infusion Grade 200000
Maximum Post-Infusion Grade 310100
Maximum Post-Infusion Grade 400000
SecondaryShort Term Tolerance - Change in Systolic Blood Pressure: Immune Globulin Administered Intravenously (Human), 10% (IV 10%), Infusion 2

Vital signs measured pre-infusion, during infusion, and post-infusion of Immune globulin administered intravenously (Human), 10% (IV 10%) was graded by the investigator and the sponsor using a 4-grade scale: mild (grade 1), moderate (grade 2), severe (grade 3) or life-threatening (grade 4) according to the U.S. Department of Health and Human Services, Food and Drug Administration, Center for Biologics Evaluation and Research; Guidance for Industry - Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials, September2007. \*Note 5th Grade (grade 0) added to scale to reflect within normal range.

Time frame:
Within 30 minutes pre-infusion, during infusion and within 30 minutes post infusion
Reported as:
Count of participants · Participants
Short Term Tolerance - Change in Systolic Blood Pressure: Immune Globulin Administered Intravenously (Human), 10% (IV 10%), Infusion 2
ParticipantsPre-Infusion Toxicity Grade 0Pre-Infusion Toxicity Grade 1Pre-Infusion Toxicity Grade 2Pre-Infusion Toxicity Grade 3Pre-Infusion Toxicity Grade 4
Maximum Post-Infusion Grade 0620000
Maximum Post-Infusion Grade 152000
Maximum Post-Infusion Grade 210100
Maximum Post-Infusion Grade 320100
Maximum Post-Infusion Grade 400000
SecondaryShort Term Tolerance - Change in Systolic Blood Pressure: Immune Globulin Administered Intravenously (Human), 10% (IV 10%), Infusion 3

Vital signs measured pre-infusion, during infusion, and post-infusion of Immune globulin administered intravenously (Human), 10% (IV 10%) was graded by the investigator and the sponsor using a 4-grade scale: mild (grade 1), moderate (grade 2), severe (grade 3) or life-threatening (grade 4) according to the U.S. Department of Health and Human Services, Food and Drug Administration, Center for Biologics Evaluation and Research; Guidance for Industry - Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials, September2007. \*Note 5th Grade (grade 0) added to scale to reflect within normal range.

Time frame:
Within 30 minutes pre-infusion, during infusion and within 30 minutes post infusion
Reported as:
Count of participants · Participants
Short Term Tolerance - Change in Systolic Blood Pressure: Immune Globulin Administered Intravenously (Human), 10% (IV 10%), Infusion 3
ParticipantsPre-Infusion Toxicity Grade 0Pre-Infusion Toxicity Grade 1Pre-Infusion Toxicity Grade 2Pre-Infusion Toxicity Grade 3Pre-Infusion Toxicity Grade 4
Maximum Post-Infusion Grade 0590000
Maximum Post-Infusion Grade 192200
Maximum Post-Infusion Grade 210000
Maximum Post-Infusion Grade 300100
Maximum Post-Infusion Grade 400000
SecondaryShort Term Tolerance - Change in Systolic Blood Pressure: Immune Globulin Administered Subcutaneously (Human), 20% (SC 20%), Infusion 1

Vital signs measured pre-infusion, during infusion, and post-infusion of Immune globulin administered subcutaneously (Human), 20% (SC 20%) was graded by the investigator and the sponsor using a 4-grade scale: mild (grade 1), moderate (grade 2), severe (grade 3) or life-threatening (grade 4) according to the U.S. Department of Health and Human Services, Food and Drug Administration, Center for Biologics Evaluation and Research; Guidance for Industry - Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials, September2007. \*Note 5th Grade (grade 0) added to scale to reflect within normal range.

Time frame:
Within 30 minutes pre-infusion, during infusion and within 30 minutes post infusion
Reported as:
Count of participants · Participants
Short Term Tolerance - Change in Systolic Blood Pressure: Immune Globulin Administered Subcutaneously (Human), 20% (SC 20%), Infusion 1
ParticipantsPre-Infusion Toxicity Grade 0Pre-Infusion Toxicity Grade 1Pre-Infusion Toxicity Grade 2Pre-Infusion Toxicity Grade 3Pre-Infusion Toxicity Grade 4
Maximum Post-Infusion Grade 0381000
Maximum Post-Infusion Grade 110000
Maximum Post-Infusion Grade 221100
Maximum Post-Infusion Grade 301000
Maximum Post-Infusion Grade 400000
SecondaryShort Term Tolerance - Change in Systolic Blood Pressure: Immune Globulin Administered Subcutaneously (Human), 20% (SC 20%), Infusion 2

Vital signs measured pre-infusion, during infusion, and post-infusion of Immune globulin administered subcutaneously (Human), 20% (SC 20%) was graded by the investigator and the sponsor using a 4-grade scale: mild (grade 1), moderate (grade 2), severe (grade 3) or life-threatening (grade 4) according to the U.S. Department of Health and Human Services, Food and Drug Administration, Center for Biologics Evaluation and Research; Guidance for Industry - Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials, September2007. \*Note 5th Grade (grade 0) added to scale to reflect within normal range.

Time frame:
Within 30 minutes pre-infusion, during infusion and within 30 minutes post infusion
Reported as:
Count of participants · Participants
Short Term Tolerance - Change in Systolic Blood Pressure: Immune Globulin Administered Subcutaneously (Human), 20% (SC 20%), Infusion 2
ParticipantsPre-Infusion Toxicity Grade 0Pre-Infusion Toxicity Grade 1Pre-Infusion Toxicity Grade 2Pre-Infusion Toxicity Grade 3Pre-Infusion Toxicity Grade 4
Maximum Post-Infusion Grade 0352000
Maximum Post-Infusion Grade 121000
Maximum Post-Infusion Grade 200000
Maximum Post-Infusion Grade 300010
Maximum Post-Infusion Grade 400000
SecondaryShort Term Tolerance - Change in Systolic Blood Pressure: Immune Globulin Administered Subcutaneously (Human), 20% (SC 20%), Infusion 3

Vital signs measured pre-infusion, during infusion, and post-infusion of Immune globulin administered subcutaneously (Human), 20% (SC 20%) was graded by the investigator and the sponsor using a 4-grade scale: mild (grade 1), moderate (grade 2), severe (grade 3) or life-threatening (grade 4) according to the U.S. Department of Health and Human Services, Food and Drug Administration, Center for Biologics Evaluation and Research; Guidance for Industry - Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials, September2007. \*Note 5th Grade (grade 0) added to scale to reflect within normal range.

Time frame:
Within 30 minutes pre-infusion, during infusion and within 30 minutes post infusion
Reported as:
Count of participants · Participants
Short Term Tolerance - Change in Systolic Blood Pressure: Immune Globulin Administered Subcutaneously (Human), 20% (SC 20%), Infusion 3
ParticipantsPre-Infusion Toxicity Grade 0Pre-Infusion Toxicity Grade 1Pre-Infusion Toxicity Grade 2Pre-Infusion Toxicity Grade 3Pre-Infusion Toxicity Grade 4
Maximum Post-Infusion Grade 0320000
Maximum Post-Infusion Grade 121000
Maximum Post-Infusion Grade 200000
Maximum Post-Infusion Grade 300010
Maximum Post-Infusion Grade 400000
SecondaryShort Term Tolerance - Change in Diastolic Blood Pressure: Immune Globulin Administered Intravenously (Human), 10% (IV 10%), Infusion 1

Vital signs measured pre-infusion, during infusion, and post-infusion of Immune globulin administered intravenously (Human), 10% (IV 10%) was graded by the investigator and the sponsor using a 4-grade scale: mild (grade 1), moderate (grade 2), severe (grade 3) or life-threatening (grade 4) according to the U.S. Department of Health and Human Services, Food and Drug Administration, Center for Biologics Evaluation and Research; Guidance for Industry - Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials, September2007. \*Note 5th Grade (grade 0) added to scale to reflect within normal range.

Time frame:
Within 30 minutes pre-infusion, during infusion and within 30 minutes post infusion
Reported as:
Count of participants · Participants
Short Term Tolerance - Change in Diastolic Blood Pressure: Immune Globulin Administered Intravenously (Human), 10% (IV 10%), Infusion 1
ParticipantsPre-Infusion Toxicity Grade 0Pre-Infusion Toxicity Grade 1Pre-Infusion Toxicity Grade 2Pre-Infusion Toxicity Grade 3Pre-Infusion Toxicity Grade 4
Maximum Post-Infusion Grade 0690100
Maximum Post-Infusion Grade 120200
Maximum Post-Infusion Grade 201010
Maximum Post-Infusion Grade 310000
Maximum Post-Infusion Grade 400000
SecondaryShort Term Tolerance - Change in Diastolic Blood Pressure: Immune Globulin Administered Intravenously (Human), 10% (IV 10%), Infusion 2

Vital signs measured pre-infusion, during infusion, and post-infusion of Immune globulin administered intravenously (Human), 10% (IV 10%) was graded by the investigator and the sponsor using a 4-grade scale: mild (grade 1), moderate (grade 2), severe (grade 3) or life-threatening (grade 4) according to the U.S. Department of Health and Human Services, Food and Drug Administration, Center for Biologics Evaluation and Research; Guidance for Industry - Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials, September2007. \*Note 5th Grade (grade 0) added to scale to reflect within normal range.

Time frame:
Within 30 minutes pre-infusion, during infusion and within 30 minutes post infusion
Reported as:
Count of participants · Participants
Short Term Tolerance - Change in Diastolic Blood Pressure: Immune Globulin Administered Intravenously (Human), 10% (IV 10%), Infusion 2
ParticipantsPre-Infusion Toxicity Grade 0Pre-Infusion Toxicity Grade 1Pre-Infusion Toxicity Grade 2Pre-Infusion Toxicity Grade 3Pre-Infusion Toxicity Grade 4
Maximum Post-Infusion Grade 0670100
Maximum Post-Infusion Grade 130000
Maximum Post-Infusion Grade 212000
Maximum Post-Infusion Grade 300000
Maximum Post-Infusion Grade 400000
SecondaryShort Term Tolerance - Change in Diastolic Blood Pressure: Immune Globulin Administered Intravenously (Human), 10% (IV 10%), Infusion 3

Vital signs measured pre-infusion, during infusion, and post-infusion of Immune globulin administered intravenously (Human), 10% (IV 10%) was graded by the investigator and the sponsor using a 4-grade scale: mild (grade 1), moderate (grade 2), severe (grade 3) or life-threatening (grade 4) according to the U.S. Department of Health and Human Services, Food and Drug Administration, Center for Biologics Evaluation and Research; Guidance for Industry - Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials, September2007. \*Note 5th Grade (grade 0) added to scale to reflect within normal range.

Time frame:
Within 30 minutes pre-infusion, during infusion and within 30 minutes post infusion
Reported as:
Count of participants · Participants
Short Term Tolerance - Change in Diastolic Blood Pressure: Immune Globulin Administered Intravenously (Human), 10% (IV 10%), Infusion 3
ParticipantsPre-Infusion Toxicity Grade 0Pre-Infusion Toxicity Grade 1Pre-Infusion Toxicity Grade 2Pre-Infusion Toxicity Grade 3Pre-Infusion Toxicity Grade 4
Maximum Post-Infusion Grade 0691000
Maximum Post-Infusion Grade 112000
Maximum Post-Infusion Grade 210000
Maximum Post-Infusion Grade 300000
Maximum Post-Infusion Grade 400000
SecondaryShort Term Tolerance - Change in Diastolic Blood Pressure: Immune Globulin Administered Subcutaneously (Human), 20% (SC 20%), Infusion 1

Vital signs measured pre-infusion, during infusion, and post-infusion of Immune globulin administered subcutaneously (Human), 20% (SC 20%) was graded by the investigator and the sponsor using a 4-grade scale: mild (grade 1), moderate (grade 2), severe (grade 3) or life-threatening (grade 4) according to the U.S. Department of Health and Human Services, Food and Drug Administration, Center for Biologics Evaluation and Research; Guidance for Industry - Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials, September2007. \*Note 5th Grade (grade 0) added to scale to reflect within normal range.

Time frame:
Within 30 minutes pre-infusion, during infusion and within 30 minutes post infusion
Reported as:
Count of participants · Participants
Short Term Tolerance - Change in Diastolic Blood Pressure: Immune Globulin Administered Subcutaneously (Human), 20% (SC 20%), Infusion 1
ParticipantsPre-Infusion Toxicity Grade 0Pre-Infusion Toxicity Grade 1Pre-Infusion Toxicity Grade 2Pre-Infusion Toxicity Grade 3Pre-Infusion Toxicity Grade 4
Maximum Post-Infusion Grade 0411000
Maximum Post-Infusion Grade 101000
Maximum Post-Infusion Grade 200000
Maximum Post-Infusion Grade 311000
Maximum Post-Infusion Grade 400000
SecondaryShort Term Tolerance - Change in Diastolic Blood Pressure: Immune Globulin Administered Subcutaneously (Human), 20% (SC 20%), Infusion 2

Vital signs measured pre-infusion, during infusion, and post-infusion of Immune globulin administered subcutaneously (Human), 20% (SC 20%) was graded by the investigator and the sponsor using a 4-grade scale: mild (grade 1), moderate (grade 2), severe (grade 3) or life-threatening (grade 4) according to the U.S. Department of Health and Human Services, Food and Drug Administration, Center for Biologics Evaluation and Research; Guidance for Industry - Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials, September2007. \*Note 5th Grade (grade 0) added to scale to reflect within normal range.

Time frame:
Within 30 minutes pre-infusion, during infusion and within 30 minutes post infusion
Reported as:
Count of participants · Participants
Short Term Tolerance - Change in Diastolic Blood Pressure: Immune Globulin Administered Subcutaneously (Human), 20% (SC 20%), Infusion 2
ParticipantsPre-Infusion Toxicity Grade 0Pre-Infusion Toxicity Grade 1Pre-Infusion Toxicity Grade 2Pre-Infusion Toxicity Grade 3Pre-Infusion Toxicity Grade 4
Maximum Post-Infusion Grade 0370000
Maximum Post-Infusion Grade 121000
Maximum Post-Infusion Grade 200000
Maximum Post-Infusion Grade 300100
Maximum Post-Infusion Grade 400000
SecondaryShort Term Tolerance - Change in Diastolic Blood Pressure: Immune Globulin Administered Subcutaneously (Human), 20% (SC 20%), Infusion 3

Vital signs measured pre-infusion, during infusion, and post-infusion of Immune globulin administered subcutaneously (Human), 20% (SC 20%) was graded by the investigator and the sponsor using a 4-grade scale: mild (grade 1), moderate (grade 2), severe (grade 3) or life-threatening (grade 4) according to the U.S. Department of Health and Human Services, Food and Drug Administration, Center for Biologics Evaluation and Research; Guidance for Industry - Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials, September2007. \*Note 5th Grade (grade 0) added to scale to reflect within normal range.

Time frame:
Within 30 minutes pre-infusion, during infusion and within 30 minutes post infusion
Reported as:
Count of participants · Participants
Short Term Tolerance - Change in Diastolic Blood Pressure: Immune Globulin Administered Subcutaneously (Human), 20% (SC 20%), Infusion 3
ParticipantsPre-Infusion Toxicity Grade 0Pre-Infusion Toxicity Grade 1Pre-Infusion Toxicity Grade 2Pre-Infusion Toxicity Grade 3Pre-Infusion Toxicity Grade 4
Maximum Post-Infusion Grade 0350000
Maximum Post-Infusion Grade 100000
Maximum Post-Infusion Grade 200100
Maximum Post-Infusion Grade 300000
Maximum Post-Infusion Grade 400000
SecondaryShort Term Tolerance - Change in Heart Rate (Pulse): Immune Globulin Administered Intravenously (Human), 10% (IV 10%), Infusion 1

Vital signs measured pre-infusion, during infusion, and post-infusion of Immune globulin administered intravenously (Human), 10% (IV 10%) was graded by the investigator and the sponsor using a 4-grade scale: mild (grade 1), moderate (grade 2), severe (grade 3) or life-threatening (grade 4) according to the U.S. Department of Health and Human Services, Food and Drug Administration, Center for Biologics Evaluation and Research; Guidance for Industry - Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials, September2007. \*Note 5th Grade (grade 0) added to scale to reflect within normal range.

Time frame:
Within 30 minutes pre-infusion, during infusion and within 30 minutes post infusion
Reported as:
Count of participants · Participants
Short Term Tolerance - Change in Heart Rate (Pulse): Immune Globulin Administered Intravenously (Human), 10% (IV 10%), Infusion 1
ParticipantsPre-Infusion Toxicity Grade 0Pre-Infusion Toxicity Grade 1Pre-Infusion Toxicity Grade 2Pre-Infusion Toxicity Grade 3Pre-Infusion Toxicity Grade 4
Maximum Post-Infusion Grade 0613000
Maximum Post-Infusion Grade 180000
Maximum Post-Infusion Grade 221000
Maximum Post-Infusion Grade 300110
Maximum Post-Infusion Grade 400000
SecondaryShort Term Tolerance - Change in Heart Rate (Pulse): Immune Globulin Administered Intravenously (Human), 10% (IV 10%), Infusion 2

Vital signs measured pre-infusion, during infusion, and post-infusion of Immune globulin administered intravenously (Human), 10% (IV 10%) was graded by the investigator and the sponsor using a 4-grade scale: mild (grade 1), moderate (grade 2), severe (grade 3) or life-threatening (grade 4) according to the U.S. Department of Health and Human Services, Food and Drug Administration, Center for Biologics Evaluation and Research; Guidance for Industry - Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials, September2007. \*Note 5th Grade (grade 0) added to scale to reflect within normal range.

Time frame:
Within 30 minutes pre-infusion, during infusion and within 30 minutes post infusion
Reported as:
Count of participants · Participants
Short Term Tolerance - Change in Heart Rate (Pulse): Immune Globulin Administered Intravenously (Human), 10% (IV 10%), Infusion 2
ParticipantsPre-Infusion Toxicity Grade 0Pre-Infusion Toxicity Grade 1Pre-Infusion Toxicity Grade 2Pre-Infusion Toxicity Grade 3Pre-Infusion Toxicity Grade 4
Maximum Post-Infusion Grade 0533100
Maximum Post-Infusion Grade 192000
Maximum Post-Infusion Grade 240100
Maximum Post-Infusion Grade 301000
Maximum Post-Infusion Grade 400000
SecondaryShort Term Tolerance - Change in Heart Rate (Pulse): Immune Globulin Administered Intravenously (Human), 10% (IV 10%), Infusion 3

Vital signs measured pre-infusion, during infusion, and post-infusion of Immune globulin administered intravenously (Human), 10% (IV 10%) was graded by the investigator and the sponsor using a 4-grade scale: mild (grade 1), moderate (grade 2), severe (grade 3) or life-threatening (grade 4) according to the U.S. Department of Health and Human Services, Food and Drug Administration, Center for Biologics Evaluation and Research; Guidance for Industry - Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials, September2007. \*Note 5th Grade (grade 0) added to scale to reflect within normal range.

Time frame:
Within 30 minutes pre-infusion, during infusion and within 30 minutes post infusion
Reported as:
Count of participants · Participants
Short Term Tolerance - Change in Heart Rate (Pulse): Immune Globulin Administered Intravenously (Human), 10% (IV 10%), Infusion 3
ParticipantsPre-Infusion Toxicity Grade 0Pre-Infusion Toxicity Grade 1Pre-Infusion Toxicity Grade 2Pre-Infusion Toxicity Grade 3Pre-Infusion Toxicity Grade 4
Maximum Post-Infusion Grade 0551000
Maximum Post-Infusion Grade 192100
Maximum Post-Infusion Grade 222200
Maximum Post-Infusion Grade 300000
Maximum Post-Infusion Grade 400000
SecondaryShort Term Tolerance - Change in Heart Rate (Pulse): Immune Globulin Administered Subcutaneously (Human), 20% (SC 20%), Infusion 1

Vital signs measured pre-infusion, during infusion, and post-infusion of Immune globulin administered subcutaneously (Human), 20% (SC 20%) was graded by the investigator and the sponsor using a 4-grade scale: mild (grade 1), moderate (grade 2), severe (grade 3) or life-threatening (grade 4) according to the U.S. Department of Health and Human Services, Food and Drug Administration, Center for Biologics Evaluation and Research; Guidance for Industry - Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials, September2007. \*Note 5th Grade (grade 0) added to scale to reflect within normal range.

Time frame:
Within 30 minutes pre-infusion, during infusion and within 30 minutes post infusion
Reported as:
Count of participants · Participants
Short Term Tolerance - Change in Heart Rate (Pulse): Immune Globulin Administered Subcutaneously (Human), 20% (SC 20%), Infusion 1
ParticipantsPre-Infusion Toxicity Grade 0Pre-Infusion Toxicity Grade 1Pre-Infusion Toxicity Grade 2Pre-Infusion Toxicity Grade 3Pre-Infusion Toxicity Grade 4
Maximum Post-Infusion Grade 0400000
Maximum Post-Infusion Grade 112000
Maximum Post-Infusion Grade 220000
Maximum Post-Infusion Grade 300000
Maximum Post-Infusion Grade 400000
SecondaryShort Term Tolerance - Change in Heart Rate (Pulse): Immune Globulin Administered Subcutaneously (Human), 20% (SC 20%), Infusion 2

Vital signs measured pre-infusion, during infusion, and post-infusion of Immune globulin administered subcutaneously (Human), 20% (SC 20%) was graded by the investigator and the sponsor using a 4-grade scale: mild (grade 1), moderate (grade 2), severe (grade 3) or life-threatening (grade 4) according to the U.S. Department of Health and Human Services, Food and Drug Administration, Center for Biologics Evaluation and Research; Guidance for Industry - Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials, September2007. \*Note 5th Grade (grade 0) added to scale to reflect within normal range.

Time frame:
Within 30 minutes pre-infusion, during infusion and within 30 minutes post infusion
Reported as:
Count of participants · Participants
Short Term Tolerance - Change in Heart Rate (Pulse): Immune Globulin Administered Subcutaneously (Human), 20% (SC 20%), Infusion 2
ParticipantsPre-Infusion Toxicity Grade 0Pre-Infusion Toxicity Grade 1Pre-Infusion Toxicity Grade 2Pre-Infusion Toxicity Grade 3Pre-Infusion Toxicity Grade 4
Maximum Post-Infusion Grade 0360000
Maximum Post-Infusion Grade 122000
Maximum Post-Infusion Grade 210000
Maximum Post-Infusion Grade 300000
Maximum Post-Infusion Grade 400000
SecondaryShort Term Tolerance - Change in Heart Rate (Pulse): Immune Globulin Administered Subcutaneously (Human), 20% (SC 20%), Infusion 3

Vital signs measured pre-infusion, during infusion, and post-infusion of Immune globulin administered subcutaneously (Human), 20% (SC 20%) was graded by the investigator and the sponsor using a 4-grade scale: mild (grade 1), moderate (grade 2), severe (grade 3) or life-threatening (grade 4) according to the U.S. Department of Health and Human Services, Food and Drug Administration, Center for Biologics Evaluation and Research; Guidance for Industry - Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials, September2007. \*Note 5th Grade (grade 0) added to scale to reflect within normal range.

Time frame:
Within 30 minutes pre-infusion, during infusion and within 30 minutes post infusion
Reported as:
Count of participants · Participants
Short Term Tolerance - Change in Heart Rate (Pulse): Immune Globulin Administered Subcutaneously (Human), 20% (SC 20%), Infusion 3
ParticipantsPre-Infusion Toxicity Grade 0Pre-Infusion Toxicity Grade 1Pre-Infusion Toxicity Grade 2Pre-Infusion Toxicity Grade 3Pre-Infusion Toxicity Grade 4
Maximum Post-Infusion Grade 0322000
Maximum Post-Infusion Grade 111000
Maximum Post-Infusion Grade 200000
Maximum Post-Infusion Grade 300000
Maximum Post-Infusion Grade 400000
SecondaryShort Term Tolerance - Change in Respiratory Rate: Immune Globulin Administered Intravenously (Human), 10% (IV 10%), Infusion 1

Vital signs measured pre-infusion, during infusion, and post-infusion of Immune globulin administered intravenously (Human), 10% (IV 10%) was graded by the investigator and the sponsor using a 4-grade scale: mild (grade 1), moderate (grade 2), severe (grade 3) or life-threatening (grade 4) according to the U.S. Department of Health and Human Services, Food and Drug Administration, Center for Biologics Evaluation and Research; Guidance for Industry - Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials, September2007. \*Note 5th Grade (grade 0) added to scale to reflect within normal range.

Time frame:
Within 30 minutes pre-infusion, during infusion and within 30 minutes post infusion
Reported as:
Count of participants · Participants
Short Term Tolerance - Change in Respiratory Rate: Immune Globulin Administered Intravenously (Human), 10% (IV 10%), Infusion 1
ParticipantsPre-Infusion Toxicity Grade 0Pre-Infusion Toxicity Grade 1Pre-Infusion Toxicity Grade 2Pre-Infusion Toxicity Grade 3Pre-Infusion Toxicity Grade 4
Maximum Post-Infusion Grade 0325000
Maximum Post-Infusion Grade 1728100
Maximum Post-Infusion Grade 202200
Maximum Post-Infusion Grade 300000
Maximum Post-Infusion Grade 400000
SecondaryShort Term Tolerance - Change in Respiratory Rate: Immune Globulin Administered Intravenously (Human), 10% (IV 10%), Infusion 2

Vital signs measured pre-infusion, during infusion, and post-infusion of Immune globulin administered intravenously (Human), 10% (IV 10%) was graded by the investigator and the sponsor using a 4-grade scale: mild (grade 1), moderate (grade 2), severe (grade 3) or life-threatening (grade 4) according to the U.S. Department of Health and Human Services, Food and Drug Administration, Center for Biologics Evaluation and Research; Guidance for Industry - Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials, September2007. \*Note 5th Grade (grade 0) added to scale to reflect within normal range.

Time frame:
Within 30 minutes pre-infusion, during infusion and within 30 minutes post infusion
Reported as:
Count of participants · Participants
Short Term Tolerance - Change in Respiratory Rate: Immune Globulin Administered Intravenously (Human), 10% (IV 10%), Infusion 2
ParticipantsPre-Infusion Toxicity Grade 0Pre-Infusion Toxicity Grade 1Pre-Infusion Toxicity Grade 2Pre-Infusion Toxicity Grade 3Pre-Infusion Toxicity Grade 4
Maximum Post-Infusion Grade 0352000
Maximum Post-Infusion Grade 11119100
Maximum Post-Infusion Grade 201200
Maximum Post-Infusion Grade 301020
Maximum Post-Infusion Grade 400000
SecondaryShort Term Tolerance - Change in Respiratory Rate: Immune Globulin Administered Intravenously (Human), 10% (IV 10%), Infusion 3

Vital signs measured pre-infusion, during infusion, and post-infusion of Immune globulin administered intravenously (Human), 10% (IV 10%) was graded by the investigator and the sponsor using a 4-grade scale: mild (grade 1), moderate (grade 2), severe (grade 3) or life-threatening (grade 4) according to the U.S. Department of Health and Human Services, Food and Drug Administration, Center for Biologics Evaluation and Research; Guidance for Industry - Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials, September2007. \*Note 5th Grade (grade 0) added to scale to reflect within normal range.

Time frame:
Within 30 minutes pre-infusion, during infusion and within 30 minutes post infusion
Reported as:
Count of participants · Participants
Short Term Tolerance - Change in Respiratory Rate: Immune Globulin Administered Intravenously (Human), 10% (IV 10%), Infusion 3
ParticipantsPre-Infusion Toxicity Grade 0Pre-Infusion Toxicity Grade 1Pre-Infusion Toxicity Grade 2Pre-Infusion Toxicity Grade 3Pre-Infusion Toxicity Grade 4
Maximum Post-Infusion Grade 0324000
Maximum Post-Infusion Grade 1626200
Maximum Post-Infusion Grade 202010
Maximum Post-Infusion Grade 300010
Maximum Post-Infusion Grade 400000
SecondaryShort Term Tolerance - Change in Respiratory Rate: Immune Globulin Administered Subcutaneously (Human), 20% (SC 20%), Infusion 1

Vital signs measured pre-infusion, during infusion, and post-infusion of Immune globulin administered subcutaneously (Human), 20% (SC 20%) was graded by the investigator and the sponsor using a 4-grade scale: mild (grade 1), moderate (grade 2), severe (grade 3) or life-threatening (grade 4) according to the U.S. Department of Health and Human Services, Food and Drug Administration, Center for Biologics Evaluation and Research; Guidance for Industry - Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials, September2007. \*Note 5th Grade (grade 0) added to scale to reflect within normal range.

Time frame:
Within 30 minutes pre-infusion, during infusion and within 30 minutes post infusion
Reported as:
Count of participants · Participants
Short Term Tolerance - Change in Respiratory Rate: Immune Globulin Administered Subcutaneously (Human), 20% (SC 20%), Infusion 1
ParticipantsPre-Infusion Toxicity Grade 0Pre-Infusion Toxicity Grade 1Pre-Infusion Toxicity Grade 2Pre-Infusion Toxicity Grade 3Pre-Infusion Toxicity Grade 4
Maximum Post-Infusion Grade 0181000
Maximum Post-Infusion Grade 1917000
Maximum Post-Infusion Grade 200000
Maximum Post-Infusion Grade 300000
Maximum Post-Infusion Grade 400000
SecondaryShort Term Tolerance - Change in Respiratory Rate: Immune Globulin Administered Subcutaneously (Human), 20% (SC 20%), Infusion 2

Vital signs measured pre-infusion, during infusion, and post-infusion of Immune globulin administered subcutaneously (Human), 20% (SC 20%) was graded by the investigator and the sponsor using a 4-grade scale: mild (grade 1), moderate (grade 2), severe (grade 3) or life-threatening (grade 4) according to the U.S. Department of Health and Human Services, Food and Drug Administration, Center for Biologics Evaluation and Research; Guidance for Industry - Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials, September2007. \*Note 5th Grade (grade 0) added to scale to reflect within normal range.

Time frame:
Within 30 minutes pre-infusion, during infusion and within 30 minutes post infusion
Reported as:
Count of participants · Participants
Short Term Tolerance - Change in Respiratory Rate: Immune Globulin Administered Subcutaneously (Human), 20% (SC 20%), Infusion 2
ParticipantsPre-Infusion Toxicity Grade 0Pre-Infusion Toxicity Grade 1Pre-Infusion Toxicity Grade 2Pre-Infusion Toxicity Grade 3Pre-Infusion Toxicity Grade 4
Maximum Post-Infusion Grade 0181000
Maximum Post-Infusion Grade 1418000
Maximum Post-Infusion Grade 200000
Maximum Post-Infusion Grade 300000
Maximum Post-Infusion Grade 400000
SecondaryShort Term Tolerance - Change in Respiratory Rate: Immune Globulin Administered Subcutaneously (Human), 20% (SC 20%), Infusion 3

Vital signs measured pre-infusion, during infusion, and post-infusion of Immune globulin administered subcutaneously (Human), 20% (SC 20%) was graded by the investigator and the sponsor using a 4-grade scale: mild (grade 1), moderate (grade 2), severe (grade 3) or life-threatening (grade 4) according to the U.S. Department of Health and Human Services, Food and Drug Administration, Center for Biologics Evaluation and Research; Guidance for Industry - Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials, September2007. \*Note 5th Grade (grade 0) added to scale to reflect within normal range.

Time frame:
Within 30 minutes pre-infusion, during infusion and within 30 minutes post infusion
Reported as:
Count of participants · Participants
Short Term Tolerance - Change in Respiratory Rate: Immune Globulin Administered Subcutaneously (Human), 20% (SC 20%), Infusion 3
ParticipantsPre-Infusion Toxicity Grade 0Pre-Infusion Toxicity Grade 1Pre-Infusion Toxicity Grade 2Pre-Infusion Toxicity Grade 3Pre-Infusion Toxicity Grade 4
Maximum Post-Infusion Grade 0136000
Maximum Post-Infusion Grade 1511100
Maximum Post-Infusion Grade 200000
Maximum Post-Infusion Grade 300000
Maximum Post-Infusion Grade 400000
SecondaryShort Term Tolerance - Change in Body Temperature: Immune Globulin Administered Intravenously (Human), 10% (IV 10%), Infusion 1

Vital signs measured pre-infusion, during infusion, and post-infusion of Immune globulin administered subcutaneously (Human), 20% (SC 20%) was graded by the investigator and the sponsor using a 4-grade scale: mild (grade 1), moderate (grade 2), severe (grade 3) or life-threatening (grade 4) according to the U.S. Department of Health and Human Services, Food and Drug Administration, Center for Biologics Evaluation and Research; Guidance for Industry - Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials, September2007. \*Note 5th Grade (grade 0) added to scale to reflect within normal range.

Time frame:
Within 30 minutes pre-infusion, during infusion and within 30 minutes post infusion
Reported as:
Count of participants · Participants
Short Term Tolerance - Change in Body Temperature: Immune Globulin Administered Intravenously (Human), 10% (IV 10%), Infusion 1
ParticipantsPre-Infusion Toxicity Grade 0Pre-Infusion Toxicity Grade 1Pre-Infusion Toxicity Grade 2Pre-Infusion Toxicity Grade 3Pre-Infusion Toxicity Grade 4
Maximum Post-Infusion Grade 0770000
Maximum Post-Infusion Grade 100000
Maximum Post-Infusion Grade 200000
Maximum Post-Infusion Grade 300000
Maximum Post-Infusion Grade 400000
SecondaryShort Term Tolerance - Change in Body Temperature: Immune Globulin Administered Intravenously (Human), 10% (IV 10%), Infusion 2

Vital signs measured pre-infusion, during infusion, and post-infusion of Immune globulin administered intravenously (Human), 10% (IV 10%) was graded by the investigator and the sponsor using a 4-grade scale: mild (grade 1), moderate (grade 2), severe (grade 3) or life-threatening (grade 4) according to the U.S. Department of Health and Human Services, Food and Drug Administration, Center for Biologics Evaluation and Research; Guidance for Industry - Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials, September2007. \*Note 5th Grade (grade 0) added to scale to reflect within normal range.

Time frame:
Within 30 minutes pre-infusion, during infusion and within 30 minutes post infusion
Reported as:
Count of participants · Participants
Short Term Tolerance - Change in Body Temperature: Immune Globulin Administered Intravenously (Human), 10% (IV 10%), Infusion 2
ParticipantsPre-Infusion Toxicity Grade 0Pre-Infusion Toxicity Grade 1Pre-Infusion Toxicity Grade 2Pre-Infusion Toxicity Grade 3Pre-Infusion Toxicity Grade 4
Maximum Post-Infusion Grade 0730000
Maximum Post-Infusion Grade 110000
Maximum Post-Infusion Grade 200000
Maximum Post-Infusion Grade 300000
Maximum Post-Infusion Grade 400000
SecondaryShort Term Tolerance - Change in Body Temperature: Immune Globulin Administered Intravenously (Human), 10% (IV 10%), Infusion 3

Vital signs measured pre-infusion, during infusion, and post-infusion of Immune globulin administered intravenously (Human), 10% (IV 10%) was graded by the investigator and the sponsor using a 4-grade scale: mild (grade 1), moderate (grade 2), severe (grade 3) or life-threatening (grade 4) according to the U.S. Department of Health and Human Services, Food and Drug Administration, Center for Biologics Evaluation and Research; Guidance for Industry - Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials, September2007. \*Note 5th Grade (grade 0) added to scale to reflect within normal range.

Time frame:
Within 30 minutes pre-infusion, during infusion and within 30 minutes post infusion
Reported as:
Count of participants · Participants
Short Term Tolerance - Change in Body Temperature: Immune Globulin Administered Intravenously (Human), 10% (IV 10%), Infusion 3
ParticipantsPre-Infusion Toxicity Grade 0Pre-Infusion Toxicity Grade 1Pre-Infusion Toxicity Grade 2Pre-Infusion Toxicity Grade 3Pre-Infusion Toxicity Grade 4
Maximum Post-Infusion Grade 0720000
Maximum Post-Infusion Grade 120000
Maximum Post-Infusion Grade 200000
Maximum Post-Infusion Grade 300000
Maximum Post-Infusion Grade 400000
SecondaryShort Term Tolerance - Change in Body Temperature: Immune Globulin Administered Subcutaneously (Human), 20% (SC 20%), Infusion 1

Vital signs measured pre-infusion, during infusion, and post-infusion of Immune globulin administered subcutaneously (Human), 20% (SC 20%) was graded by the investigator and the sponsor using a 4-grade scale: mild (grade 1), moderate (grade 2), severe (grade 3) or life-threatening (grade 4) according to the U.S. Department of Health and Human Services, Food and Drug Administration, Center for Biologics Evaluation and Research; Guidance for Industry - Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials, September2007. \*Note 5th Grade (grade 0) added to scale to reflect within normal range.

Time frame:
Within 30 minutes pre-infusion, during infusion and within 30 minutes post infusion
Reported as:
Count of participants · Participants
Short Term Tolerance - Change in Body Temperature: Immune Globulin Administered Subcutaneously (Human), 20% (SC 20%), Infusion 1
ParticipantsPre-Infusion Toxicity Grade 0Pre-Infusion Toxicity Grade 1Pre-Infusion Toxicity Grade 2Pre-Infusion Toxicity Grade 3Pre-Infusion Toxicity Grade 4
Maximum Post-Infusion Grade 0450000
Maximum Post-Infusion Grade 100000
Maximum Post-Infusion Grade 200000
Maximum Post-Infusion Grade 300000
Maximum Post-Infusion Grade 400000
SecondaryShort Term Tolerance - Change in Body Temperature: Immune Globulin Administered Subcutaneously (Human), 20% (SC 20%), Infusion 2

Vital signs measured pre-infusion, during infusion, and post-infusion of Immune globulin administered subcutaneously (Human), 20% (SC 20%) was graded by the investigator and the sponsor using a 4-grade scale: mild (grade 1), moderate (grade 2), severe (grade 3) or life-threatening (grade 4) according to the U.S. Department of Health and Human Services, Food and Drug Administration, Center for Biologics Evaluation and Research; Guidance for Industry - Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials, September2007. \*Note 5th Grade (grade 0) added to scale to reflect within normal range.

Time frame:
Within 30 minutes pre-infusion, during infusion and within 30 minutes post infusion
Reported as:
Count of participants · Participants
Short Term Tolerance - Change in Body Temperature: Immune Globulin Administered Subcutaneously (Human), 20% (SC 20%), Infusion 2
ParticipantsPre-Infusion Toxicity Grade 0Pre-Infusion Toxicity Grade 1Pre-Infusion Toxicity Grade 2Pre-Infusion Toxicity Grade 3Pre-Infusion Toxicity Grade 4
Maximum Post-Infusion Grade 0410000
Maximum Post-Infusion Grade 100000
Maximum Post-Infusion Grade 200000
Maximum Post-Infusion Grade 300000
Maximum Post-Infusion Grade 400000
SecondaryShort Term Tolerance - Change in Body Temperature: Immune Globulin Administered Subcutaneously (Human), 20% (SC 20%), Infusion 3

Vital signs measured pre-infusion, during infusion, and post-infusion of Immune globulin administered subcutaneously (Human), 20% (SC 20%) was graded by the investigator and the sponsor using a 4-grade scale: mild (grade 1), moderate (grade 2), severe (grade 3) or life-threatening (grade 4) according to the U.S. Department of Health and Human Services, Food and Drug Administration, Center for Biologics Evaluation and Research; Guidance for Industry - Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials, September2007. \*Note 5th Grade (grade 0) added to scale to reflect within normal range.

Time frame:
Within 30 minutes pre-infusion, during infusion and within 30 minutes post infusion
Reported as:
Count of participants · Participants
Short Term Tolerance - Change in Body Temperature: Immune Globulin Administered Subcutaneously (Human), 20% (SC 20%), Infusion 3
ParticipantsPre-Infusion Toxicity Grade 0Pre-Infusion Toxicity Grade 1Pre-Infusion Toxicity Grade 2Pre-Infusion Toxicity Grade 3Pre-Infusion Toxicity Grade 4
Maximum Post-Infusion Grade 0360000
Maximum Post-Infusion Grade 100000
Maximum Post-Infusion Grade 200000
Maximum Post-Infusion Grade 300000
Maximum Post-Infusion Grade 400000
SecondaryNumber of Participants With Laboratory Confirmed Hemolysis That Occurred Following Investigational Product Administration

Laboratory tests for confirmation of potential hemolysis include Coomb's test, haptoglobin, free hemoglobin, reticulocyte count, lactate dehydrogenase (LDH), and urine hemosiderin.

Time frame:
Epoch 1: 3 week IV interval- weeks 0, 10. Epoch 1: 4 week IV interval- weeks 0, 9. Epoch 3: Subcutaneous (SC) week 9. Epoch 4: SC weeks 17, 18, 40
Reported as:
Number · Participants
Number of Participants With Laboratory Confirmed Hemolysis That Occurred Following Investigational Product Administration
ParticipantsIntravenous 10%Subcutaneous 20%
Number of Participants With Laboratory Confirmed Hemolysis That Occurred Following Investigational Product Administration00
SecondaryQuality of Life- Pediatric Quality of Life Inventory^TM (PEDS-QL^TM) (Observer: Parent) for the Age Group 2 to 7 Years

The Peds-QL is a generic Health-Related Quality of Life (HR QoL) instrument designed specifically for a pediatric population. It captures the following domains: general health/activities, feelings/emotional, social functioning, school functioning. Higher scores indicate better quality of life (QoL) for all domains of the Peds-QL. This modular instrument uses a 5-point scale: from 0 (never) to 4 (almost always). Items are reversed scored and linearly transformed to a 0-100 scale as follows: 0=100, 1=75, 2=50, 3=25, 4=0. 4 dimensions (physical, emotional, social, \& school functioning) are scored. 2 summary scores (Psychosocial Health Summary, and Physical Health Summary) are presented, along with a total score.

Time frame:
Up to 20 months (throughout entire study)
Reported as:
Median · Score on a scale
Quality of Life- Pediatric Quality of Life Inventory^TM (PEDS-QL^TM) (Observer: Parent) for the Age Group 2 to 7 Years
Score on a scaleStart of Study Epoch 1End of Study Epoch 1End of Study Epoch 3End of Study Epoch 4Change End Epoch 1 to End Epoch 3Change End Epoch 1 to End Epoch 4
Physical Functioning95.31 (68.75 to 100.00)93.75 (56.25 to 100.00)96.88 (62.50 to 100.00)92.19 (75.00 to 100.00)1.56 (-3.13 to 9.38)1.56 (-12.50 to 18.75)
Emotional Functioning95.00 (70.00 to 95.00)85.00 (50.00 to 95.00)82.50 (60.00 to 100.00)77.50 (55.00 to 85.00)0.00 (-5.00 to 10.00)-2.50 (-20.00 to 10.00)
Social Functioning95.00 (65.00 to 100.00)95.00 (25.00 to 100.00)97.50 (25.00 to 100.00)87.50 (50.00 to 100.00)0.00 (-5.00 to 10.00)0.00 (-15.00 to 25.00)
School Functioning85.00 (55.00 to 100.00)75.00 (30.00 to 83.33)81.67 (40.00 to 100.00)67.50 (25.00 to 91.67)7.50 (0.00 to 25.00)-5.00 (-10.00 to 8.33)
Psychosocial Health Summary91.67 (65.00 to 98.08)83.33 (38.33 to 92.31)84.17 (41.67 to 100.00)77.50 (46.67 to 90.38)2.50 (0.00 to 11.67)-3.33 (-8.33 to 8.33)
Physical Health Summary95.31 (68.75 to 100.00)93.75 (56.25 to 100.00)96.88 (62.50 to 100.00)92.19 (75.00 to 100.00)1.56 (-3.13 to 9.38)1.56 (-12.50 to 18.75)
Total Score92.93 (69.57 to 98.81)86.96 (59.78 to 94.05)88.04 (60.87 to 100.00)82.61 (60.87 to 94.05)1.63 (0.00 to 10.87)0.00 (-5.43 to 4.35)
SecondaryQuality of Life- PEDS-QL^TM (Observer: Participant) for the Age Group 8 to 13 Years of Age

The Peds-QL is a generic Health-Related Quality of Life (HR QoL) instrument designed specifically for a pediatric population. It captures the following domains: general health/activities, feelings/emotional, social functioning, school functioning. Higher scores indicate better quality of life (QoL) for all domains of the Peds-QL. This modular instrument uses a 5-point scale: from 0 (never) to 4 (almost always). Items are reversed scored and linearly transformed to a 0-100 scale as follows: 0=100, 1=75, 2=50, 3=25, 4=0. 4 dimensions (physical, emotional, social, \& school functioning) are scored. 2 summary scores (Psychosocial Health Summary, and Physical Health Summary) are presented, along with a total score.

Time frame:
Up to 20 months (throughout entire study)
Reported as:
Median · Score on a scale
Quality of Life- PEDS-QL^TM (Observer: Participant) for the Age Group 8 to 13 Years of Age
Score on a scaleStart of Epoch 1End of Epoch 1End of Epoch 3End of Epoch 4Change End of Epoch 1 to End of Epoch 3Change End of Epoch 1 to End of Epoch 4
Physical Functioning89.06 (81.25 to 100.00)90.63 (78.13 to 100.00)87.50 (75.00 to 100.00)93.75 (71.88 to 100.00)0.00 (-3.13 to 9.38)6.25 (0.00 to 15.63)
Emotional Functioning87.50 (75.00 to 100.00)80.00 (70.00 to 90.00)80.00 (70.00 to 95.00)87.50 (65.00 to 95.00)0.00 (-5.00 to 5.00)10.00 (-5.00 to 15.00)
Social Functioning87.50 (80.00 to 100.00)95.00 (80.00 to 100.00)95.00 (85.00 to 100.00)95.00 (85.00 to 100.00)0.00 (0.00 to 5.00)0.00 (0.00 to 5.00)
School Functioning75.00 (55.00 to 90.00)80.00 (60.00 to 85.00)75.00 (55.00 to 85.00)70.00 (55.00 to 85.00)0.00 (-10.00 to 10.00)-2.50 (-15.00 to 10.00)
Psychosocial Health Summary80.83 (76.67 to 91.67)83.33 (71.67 to 91.67)81.67 (75.00 to 93.33)81.67 (78.33 to 91.67)0.00 (-3.33 to 8.33)3.33 (-1.67 to 10.00)
Physical Health Summary89.06 (81.25 to 100.00)90.63 (78.13 to 100.00)87.50 (75.00 to 100.00)93.75 (71.88 to 100.00)0.00 (-3.13 to 9.38)6.25 (0.00 to 15.63)
Total Score86.41 (82.61 to 94.57)89.13 (69.57 to 91.30)81.52 (76.09 to 93.48)85.87 (79.35 to 92.39)1.09 (-1.09 to 7.61)2.17 (-3.26 to 10.87)
SecondaryQuality of Life- Short-Form 36v2 (SF-36v2) for the Age Group 14 Years and Older

The PCS is a summary scale of the dimensions physical functioning, role physical, bodily pain, and general health. The component score is normalized to a standard population. Scores range from 0 to 100 with higher scores representing better health. There is no total overall score; scoring is done for both sub-scores and summary scores.

Time frame:
Up to 20 months (throughout entire study)
Reported as:
Median · Scores on a scale
Quality of Life- Short-Form 36v2 (SF-36v2) for the Age Group 14 Years and Older
Scores on a scaleSTART OF STUDY EPOCH 1END OF STUDY EPOCH 1END OF STUDY EPOCH 3END OF STUDY EPOCH 4CHANGE END EPOCH 1 TO END EPOCH 3CHANGE END EPOCH 1 TO END EPOCH 4
Physical Functioning48.61 (46.51 to 52.82)52.82 (44.41 to 54.93)50.72 (48.61 to 52.82)50.72 (46.51 to 54.93)0.00 (-2.10 to 0.00)0.00 (-2.10 to 2.10)
Role-Physical44.61 (37.26 to 49.51)42.16 (37.26 to 51.96)49.51 (42.16 to 54.40)47.06 (44.61 to 51.96)2.45 (0.00 to 4.90)2.45 (0.00 to 4.90)
Bodily Pain43.95 (41.41 to 51.13)45.64 (37.18 to 50.29)50.29 (41.83 to 51.13)46.06 (41.83 to 51.13)4.23 (0.00 to 4.65)0.00 (0.00 to 4.65)
General Health38.63 (33.87 to 41.02)41.02 (33.87 to 44.83)38.63 (36.25 to 45.78)38.63 (36.25 to 45.78)0.95 (-1.43 to 2.38)0.72 (-2.38 to 2.38)
Vitality42.72 (39.60 to 48.97)42.72 (36.48 to 48.97)45.85 (39.60 to 52.09)48.97 (42.72 to 52.09)3.12 (0.00 to 3.12)1.56 (0.00 to 6.24)
Social Functioning45.94 (40.49 to 51.40)45.94 (40.49 to 51.40)51.40 (45.94 to 51.40)51.40 (45.94 to 56.85)0.00 (0.00 to 0.00)0.00 (0.00 to 5.45)
Role-Emotional51.99 (44.22 to 55.88)55.88 (48.10 to 55.88)51.99 (48.10 to 55.88)53.94 (44.22 to 55.88)0.00 (0.00 to 0.00)0.00 (0.00 to 0.00)
Mental Health50.01 (47.19 to 52.82)52.82 (47.19 to 55.64)50.01 (47.19 to 52.82)52.82 (50.01 to 55.64)0.00 (-2.82 to 2.82)1.41 (-2.82 to 2.82)
Physical Component Summary41.57 (38.01 to 47.02)39.93 (37.57 to 47.98)46.13 (43.00 to 50.84)46.07 (42.38 to 49.25)1.22 (-0.51 to 3.29)0.89 (-0.37 to 2.49)
Mental Component Summary49.92 (45.53 to 51.78)49.45 (46.87 to 53.58)49.70 (46.37 to 54.06)51.59 (48.03 to 54.35)0.57 (-2.17 to 2.39)1.31 (-3.69 to 4.40)
SecondaryTreatment Satisfaction Questionnaire for Medication (TSQM) - 2 to 12 Years Old

TSQM; for the age group 2 to 12 years the observer will be a parent. Treatment Satisfaction Questionnaire for Medication (TSQM) is a global satisfaction scale used to assess the overall level of participant's satisfaction or dissatisfaction with their medications. The following 3 domain were included: effectiveness, convenience, and global satisfaction. The score of each of the 3 domains is based on an algorithm to create a score of 0 to 100. Higher score indicated greater satisfaction in that domain.

Time frame:
Up to 20 months per subject (throughout entire study)
Reported as:
Median · Score on a scale
Treatment Satisfaction Questionnaire for Medication (TSQM) - 2 to 12 Years Old
Score on a scaleStart of Epoch 1End of Epoch 1End of Epoch 3End of Epoch 4Change End of Epoch 1 to End of Epoch 3Change End of Epoch 1 to End of Epoch 4
Effectiveness83.33 (77.78 to 100.00)88.89 (83.33 to 100.00)83.33 (66.67 to 100.00)91.67 (72.22 to 100.00)0.00 (-11.11 to 0.00)0.00 (-5.56 to 5.56)
Convenience75.00 (55.56 to 88.89)72.22 (66.67 to 83.33)80.56 (77.78 to 100.00)77.78 (77.78 to 94.44)5.56 (0.00 to 27.78)5.56 (0.00 to 16.67)
Global Satisfaction85.71 (78.57 to 100.00)92.86 (71.43 to 100.00)100.00 (71.43 to 100.00)89.29 (71.43 to 100.00)0.00 (0.00 to 7.14)0.00 (0.00 to 7.14)
SecondaryTreatment Satisfaction Questionnaire for Medication (TSQM) - 13 Years and Older

TSQM; for the age group 13 years and older the observer will be the participant. Treatment Satisfaction Questionnaire for Medication (TSQM) is a global satisfaction scale used to assess the overall level of participant's satisfaction or dissatisfaction with their medications. The following 3 domain were included: effectiveness, convenience, and global satisfaction. The score of each of the 3 domains is based on an algorithm to create a score of 0 to 100. Higher score indicated greater satisfaction in that domain.

Time frame:
Up to 20 months per subject (throughout entire study)
Reported as:
Median · Score on a scale
Treatment Satisfaction Questionnaire for Medication (TSQM) - 13 Years and Older
Score on a scaleStart of Epoch 1End of Epoch 1End of Epoch 3End of Epoch 4Change End of Epoch 1 to End of Epoch 3Change End of Epoch 1 to End of Epoch 4
Effectiveness77.78 (72.22 to 83.33)80.56 (72.22 to 88.89)83.33 (77.78 to 88.89)83.33 (77.78 to 88.89)0.00 (0.00 to 5.56)0.00 (0.00 to 5.56)
Convenience66.67 (61.11 to 77.78)66.67 (55.56 to 72.22)83.33 (72.22 to 83.33)83.33 (77.78 to 88.89)11.11 (5.56 to 16.67)11.11 (5.56 to 16.67)
Global Satisfaction85.71 (78.57 to 92.86)85.71 (78.57 to 92.86)92.86 (78.57 to 92.86)92.86 (85.71 to 92.86)0.00 (0.00 to 7.14)0.00 (0.00 to 7.14)
SecondaryLife Quality Index - 2 to 12 Years Old

For the age group 2 to 12 years the respondent will be a parent. Each of the four domains has a separate score, each has a different range as follows: Treatment Interference Score Range: 6-42, Therapy-related Problems Score Range: 4-28, Therapy Setting Score Range: 3-21, Cost Score Range: 2-14. Higher scores represent more satisfaction with various aspects of treatment.

Time frame:
Up to 20 months (throughout entire study)
Reported as:
Median · Score on a scale
Life Quality Index - 2 to 12 Years Old
Score on a scaleStart of Epoch 1End of Epoch 1End of Epoch 3End of Epoch 4Change End of Epoch 1 to End of Epoch 3Change End of Epoch 1 to End of Epoch 4
Treatment Interference32.0 (27.0 to 40.0)31.0 (30.0 to 41.0)35.0 (31.0 to 39.0)34.5 (30.0 to 39.0)0.0 (-2.0 to 5.0)-0.5 (-2.0 to 9.0)
Therapy-related Problems23.0 (20.0 to 24.0)23.0 (22.0 to 26.0)22.0 (20.0 to 24.0)21.5 (21.0 to 25.0)0.0 (-2.0 to 0.0)-1.0 (-3.0 to 0.0)
Therapy Settings18.0 (17.0 to 21.0)18.0 (16.0 to 20.0)19.0 (18.0 to 21.0)20.0 (17.0 to 21.0)0.0 (0.0 to 3.0)1.0 (-1.0 to 3.0)
Costs9.0 (8.0 to 11.0)11.0 (10.0 to 13.0)11.0 (11.0 to 12.0)10.5 (9.0 to 13.0)1.0 (0.0 to 2.0)-0.5 (-1.0 to 2.0)
SecondaryLife Quality Index - 13 Years and Older

For the age group 13 years and older the respondent will be the participant. Each of the four domains has a separate score, each has a different range as follows: Treatment Interference Score Range: 6-42, Therapy-related Problems Score Range: 4-28, Therapy Setting Score Range: 3-21, Cost Score Range: 2-14. Higher scores represent more satisfaction with various aspects of treatment.

Time frame:
Up to 20 months per subject (throughout entire study)
Reported as:
Median · Score on a scale
Life Quality Index - 13 Years and Older
Score on a scaleStart of Epoch 1End of Epoch 1End of Epoch 3End of Epoch 4Change End of Epoch 1 to End of Epoch 3Change End of Epoch 1 to End of Epoch 4
Treatment Interference34.0 (30.0 to 37.0)34.5 (32.0 to 36.0)37.0 (35.0 to 39.0)38.5 (34.0 to 40.0)1.0 (0.0 to 4.0)3.0 (0.0 to 5.0)
Therapy-related Problems23.0 (22.0 to 24.0)22.5 (21.0 to 24.0)24.0 (22.0 to 25.0)24.0 (23.0 to 25.0)0.0 (-1.0 to 2.0)1.0 (-1.0 to 2.0)
Therapy Settings18.0 (16.0 to 19.0)17.0 (16.0 to 18.0)20.0 (19.0 to 20.0)20.0 (19.0 to 21.0)1.0 (0.0 to 3.0)2.0 (0.0 to 3.0)
Costs8.0 (7.0 to 10.0)10.0 (9.0 to 10.0)11.5 (10.0 to 13.0)13.0 (11.0 to 14.0)1.0 (0.0 to 2.0)1.5 (1.0 to 3.0)

Adverse events

Collected over Throughout the 4 Study Epochs. Epoch 1: 13 weeks. Epoch 2: 12-16 weeks Epoch 3: 12 weeks Epoch 4: 40 weeks. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Study Epoch 1: Intravenous 10% Treatment—1/77 (1.3%)46/77 (59.7%)
Study Epochs 2-4: Subcutaneous 20% Treatment—2/74 (2.7%)59/74 (79.7%)
Most frequent serious events
Most frequent serious events
EventStudy Epoch 1: Intravenous 10% TreatmentStudy Epochs 2-4: Subcutaneous 20% Treatment
PneumoniaInfections and infestations0/771/74
Lung adenocarcinimaNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/771/74
HeadacheNervous system disorders1/770/74
Most frequent other events
Showing 10 of 31
Most frequent other events
EventStudy Epoch 1: Intravenous 10% TreatmentStudy Epochs 2-4: Subcutaneous 20% Treatment
HeadacheNervous system disorders23/7712/74
SinusitisInfections and infestations7/7718/74
Acute sinusitisInfections and infestations6/7715/74
Upper respiratory tract infectionInfections and infestations8/7714/74
Infusion site painGeneral disorders0/7714/74
NauseaGastrointestinal disorders6/7711/74
BronchitisNervous system disorders3/7711/74
DiarrhoeaGastrointestinal disorders4/778/74
CoughRespiratory, thoracic and mediastinal disorders2/778/74
Infusion site erythemaGeneral disorders0/778/74

Baseline characteristics

Safety Analysis Dataset: All participants who received at least one dose of immunoglobulin.

Age, Continuous
Age, Continuous(Years)Study Epochs 1-4
Median36.0 (3 to 83)
Sex: Female, Male
Sex: Female, Male(Participants)Study Epochs 1-4
Female37
Male40
08

Study locations

18 sites
  • University of California, Irvine
    Irvine, California 92697, United States
  • IMMUNOe International Research Centers
    Centennial, Colorado 80112, United States
  • Allergy Associates of the Palm Beaches
    North Palm Beach, Florida 33408, United States
  • Emory University
    Atlanta, Georgia 30322, United States
  • Rush University Medical Center
    Chicago, Illinois 60612, United States
  • Family Allergy and Asthma Research Institute
    Louisville, Kentucky 40215, United States
  • Children's Hospital New Orleans- LSUHSC School of Medicine
    New Orleans, Louisiana 70118, United States
  • Midwest Immunology Clinical and Infusion Center
    Plymouth, Minnesota 55446, United States
  • SSM Cardinal Glennon Children's Medical Center
    Saint Louis, Missouri 63104, United States
  • Montefiore Medical Center Division of Allergy/Immunology
    Bronx, New York 10461, United States
  • Oklahoma Institute of Allergy and Asthma Clinical Research
    Oklahoma City, Oklahoma 73131, United States
  • Vital Prospects Clinical Research Institute, PC
    Tulsa, Oklahoma 74136, United States
  • Dallas Allergy Immunology Research
    Dallas, Texas 75230, United States
  • Allergy Asthma and Immunology Clinic PA
    Irving, Texas 75063, United States
  • Rocky Mountain Asthma/Allergy/Immunology
    Layton, Utah 84041, United States
  • Medical College of Wisconsin
    Milwaukee, Wisconsin 53226, United States
  • Centre Hospitalier Universitaire (CHU) Sainte-Justine
    Montreal, Quebec H3H 1C5, Canada
  • Montreal Children's Hospital- McGill University health Center
    Montreal, Quebec HEH 1P3, Canada
09

References and documents

Publications

  • Al-Herz W, Bousfiha A, Casanova JL, Chapel H, Conley ME, Cunningham-Rundles C, Etzioni A, Fischer A, Franco JL, Geha RS, Hammarstrom L, Nonoyama S, Notarangelo LD, Ochs HD, Puck JM, Roifman CM, Seger R, Tang ML. Primary immunodeficiency diseases: an update on the classification from the international union of immunological societies expert committee for primary immunodeficiency. Front Immunol. 2011 Nov 8;2:54. doi: 10.3389/fimmu.2011.00054. eCollection 2011. PubMed 22566844 ↗
  • Conley ME, Notarangelo LD, Etzioni A. Diagnostic criteria for primary immunodeficiencies. Representing PAGID (Pan-American Group for Immunodeficiency) and ESID (European Society for Immunodeficiencies). Clin Immunol. 1999 Dec;93(3):190-7. doi: 10.1006/clim.1999.4799. No abstract available. PubMed 10600329 ↗
  • Li Z, McCoy B, Engl W, Yel L. Steady-State Serum IgG Trough Levels Are Adequate for Pharmacokinetic Assessment in Patients with Immunodeficiencies Receiving Subcutaneous Immune Globulin. J Clin Immunol. 2021 Aug;41(6):1331-1338. doi: 10.1007/s10875-021-00990-z. Epub 2021 May 26. PubMed 34036490 ↗
  • Suez D, Krivan G, Jolles S, Stein M, Gupta S, Paris K, van Hagen PM, Brodszki N, Engl W, Leibl H, McCoy B, Yel L. Safety and tolerability of subcutaneous immunoglobulin 20% in primary immunodeficiency diseases from two continents. Immunotherapy. 2019 Aug;11(12):1057-1065. doi: 10.2217/imt-2019-0057. Epub 2019 Jul 3. PubMed 31268374 ↗
  • Gupta S, Stein M, Hussain I, Paris K, Engl W, McCoy B, Rabbat CJ, Yel L. Tolerability of Ig20Gly during onboarding in patients with primary immunodeficiency diseases. Ann Allergy Asthma Immunol. 2019 Sep;123(3):271-279.e1. doi: 10.1016/j.anai.2019.06.004. Epub 2019 Jun 20. PubMed 31228628 ↗
  • Paris K, Haddad E, Borte M, Brodszki N, Derfalvi B, Marodi L, Hussain I, Darter A, Engl W, Leibl H, McCoy B, Yel L. Tolerability of subcutaneous immunoglobulin 20%, Ig20Gly, in pediatric patients with primary immunodeficiencies. Immunotherapy. 2019 Apr;11(5):397-406. doi: 10.2217/imt-2018-0088. Epub 2019 Jan 9. PubMed 30626238 ↗
  • Suez D, Stein M, Gupta S, Hussain I, Melamed I, Paris K, Darter A, Bourgeois C, Fritsch S, Leibl H, McCoy B, Gelmont D, Yel L. Efficacy, Safety, and Pharmacokinetics of a Novel Human Immune Globulin Subcutaneous, 20 % in Patients with Primary Immunodeficiency Diseases in North America. J Clin Immunol. 2016 Oct;36(7):700-12. doi: 10.1007/s10875-016-0327-9. Epub 2016 Aug 31. PubMed 27582171 ↗

Individual participant data

Plan to share: Yes — Takeda provides access to the de-identified individual participant data (IPD) for eligible studies to aid qualified researchers in addressing legitimate scientific objectives (Takeda's data sharing commitment is available on https://clinicaltrials.takeda.com/takedas-commitment?commitment=5). These IPDs will be provided in a secure research environment following approval of a data sharing request, and under the terms of a data sharing agreement.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Access criteria: IPD from eligible studies will be shared with qualified researchers according to the criteria and process described on https://vivli.org/ourmember/takeda/. For approved requests, the researchers will be provided access to anonymized data (to respect patient privacy in line with applicable laws and regulations) and with information necessary to address the research objectives under the terms of a data sharing agreement.

Data sharing details ↗ · vivli.org

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jan 2013 to primary completion in Mar 2015, 25 months.

Results were first posted in Feb 2017, 1 year 11 months after primary completion. A results delay was requested in May 2016.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 8, 2010
First posted
Oct 11, 2010
StartActual
Jan 28, 2013
Primary completionActual
Mar 13, 2015
CompletionActual
Mar 13, 2015
Results delay requested
May 6, 2016
Results first posted
Feb 15, 2017
Last update
Jul 20, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 20, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01218438
Responsible party
Sponsor
First posted
Oct 11, 2010
Start date
Jan 28, 2013
Primary completion
Mar 13, 2015
Completion
Mar 13, 2015
Results posted
Feb 15, 2017
Last update
Jul 20, 2021

Study contacts

Study Director
study director · Takeda

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Immunoglobulins, Intravenous · Homo sapiens whole

Start the discussion